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Abstract  
Expansion of the New York State Newborn Screening Panel and Krabbe Disease: 
A Systematic Program Evaluation 
Roberta Salveson 
The purpose of this study was to conduct a formal program evaluation of the New York 
State newborn screening for Krabbe disease (KD), a rare neurological disease with 
variable onset of symptoms to assess 1) the perceptions of stakeholders 2) KD test 
characteristics, and 3) actual program costs. Using the CDC Framework for Program 
Evaluation in Public Health, integration of qualitative and quantitative techniques was 
used to provide a comprehensive evaluation. Stakeholder input was elicited using semi-
structured interviews of medical professionals and parents and content analysis of the 
interview transcripts identified five themes: Legislative/Political, Unintended 
Consequences, Knowledge and Science, Communication, and Moral Issues. Finally, cost 
and charge data were used to calculate the cost of the KD screening program from the 
perspective of the State. Triangulation of the results provided the conclusions for practice 
and policy recommendations. Using the data from the State annual reports of 9 positive 
KD screening results, sensitivity was calculated at 100%, specificity was 99%, positive 
predictive value was 5%, negative predictive value was 100% and prevalence was 
1/100,000 births. However, the State reports did not include the 19 infants with low 
enzyme activity and mutations that could develop into later onset forms of KD. When 
these 19 infants were included, sensitivity, specificity, and negative predictive value 
remained unchanged; however, positive predictive value rose to 15%, and prevalence 
increased to 3/100,000 births. The total annual cost of the program from the perspective 
 
of the State was calculated at $750,652. For parents, the cost calculated from initial 
newborn screen to neurodiagnostic testing was $2669/family. 
Since 2006, there have been more than 1,000,000 infants screened for KD in New 
York State. While the screening has identified four infants with the early infantile form of 
the disease, there have been 24 others identified with low enzyme activity and mutations 
that may cause later onset forms of the disease, which are poorly understood. This 
unexpected finding suggests that newborns may be diagnosed with a disease that may not 
present symptomatically until adulthood. Unfortunately, the current confirmatory enzyme 
test and neurodiagnostic tests cannot predict onset of disease or severity of symptoms. In 
addition, the only available treatment, a cord blood transplant, is irreversible, has a high 
risk of morbidity and mortality, and long term outcomes have not been studied. While the 
cost of the program from the perspective of the state is not excessive, cost-effectiveness 
studies are needed to determine the cost of KD screening from the societal perspective, 
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Chapter I: Introduction 
Background 
 Newborn screening programs were first mandated nationally in the 1960’s to detect 
conditions that can be life threatening or cause long-term disabilities. The United States 
(US) has been the global leader in newborn screening, with the first program 
implemented in Massachusetts in 1965 (Crowe, 2008).Recognized as a valuable public 
health service, screening is aimed at providing early intervention or treatment to reduce 
mortality, morbidity, and other associated disabilities.  
 Each state in the US is granted the responsibility of governing its own newborn 
screening program. Policy decisions in each state illustrate differences in community 
values, political and economic environments, and public health technical abilities and 
resources (AAP Newborn Screening Task Force, 2000). Screening panels have expanded 
as technological advances facilitate screening for more diseases. Since 1965, the number 
of conditions included has increased from one to as many as 57, with considerable 
variability existing from state to state (National newborn screening and genetics 
resources center [NNSGRC], 2010). New York expanded its newborn screening program 
in 2003 to include more than 40 diseases, compared to other states that included as few as 
eight. In August 2006, New York became the first and only state to include Krabbe 
disease (KD) in its screening program.    
Krabbe disease is a type of leukodystrophy, a progressive neurological disease caused 
by demyelination of the white matter and peripheral nerves. It is a rare disease, with the 




2001). The disease is detected by measuring the level of the enzyme galactocerebrocidase 
(GALC) in the blood. Until recently, the more common, infantile onset form of KD was 
always fatal by 2 years of age. However, there has been some success reported in halting 
the disease process using umbilical cord blood transplantation (UUCBT) prior to 
appearance of symptoms (Escolar et al., 2005). Although this treatment option for KD 
has 10 years of follow-up data regarding physiologic outcomes, quality of life and 
specific disease morbidity have not been studied.  
In 1968, Wilson and Junger developed an initial set of principles for population 
screening panels including guidance for inclusion of new diseases (Wilson & Junger, 
1968). These principles, which are discussed in Chapter 2, have been used by some state 
legislatures as decision criteria when changing existing panels. However, as patient 
disease advocacy groups and private industry have gained increasing influence, 
legislators have other issues to consider. For example, as private laboratories develop and 
patent tests for rare diseases, adding testing for these diseases to screening panels could 
be profitable. This has resulted in lobbying by private laboratories, as well as direct 
marketing to parents (Berg & Fryer-Edwards, 2008). As pharmaceutical companies seek 
to develop new treatments or modify existing treatments for rare diseases, the pressure to 
identify new patients at the earliest age may compel their support for addition of testing 
for these diseases to newborn screening panels. Pressure may also be exerted by the 
public to employ screening even for conditions that do not have effective or necessary 
intervention and may otherwise violate the principles of population screening (AAP 




precedence over the established criteria and expert recommendations, further contributing 
to differences between state panels.  
Expansion of screening panels has been an area of concern to health care 
providers, legislators, and parents for a number of reasons, including: disparities between 
state programs, cost of testing, ability to pay for treatment of diseases that are diagnosed, 
and anxiety due to false positive test results. Since no federal entity has the authority to 
mandate what states will screen for (Green, et al, 2007), the inclusion criteria for the 
addition of new disorders remain guidelines, and thus, each state’s policy decisions 
remain variable, thus resulting in discrepancies in testing across the US.  
Determination of financing of newborn screening programs is also an individual 
state decision. Varying amounts of federal funding, generally in the form of Title V block 
grants, are used to augment legislative appropriations and fees. Only Kansas, New York, 
District of Columbia, and Pennsylvania provide newborn screening at no cost to the 
infant’s family (NNSGRC, 2010). All other states collect fees as the primary source of 
funding (Johnson, Lloyd-Puryear, Mann, Raskin-Ramos, & Bradford, 2006), ranging in 
cost from $15 in Florida to $139 in Alabama. As genetic science advances and testing 
becomes possible for more conditions, policy-makers will need objective cost and 
outcome data to assist in decisions requiring allocation of limited resources.  
Statement of the Problem  
Since state legislatures have no federal mandate to follow guidelines and public as 
well as industry pressure can exert undue influence on policy-makers’ decisions, a need 




inclusion in screening panels. Illinois, Missouri, and New Mexico have passed legislation 
to add KD testing to their existing newborn screening panels citing New York State’s 
decision as precedent for their decision (DeLuka & Woolverton, 2008). However, 
inclusion of KD to New York State’s newborn screening panel has not undergone 
systematic evaluation using objective criteria. 
A comprehensive review is needed to provide objective information to 
stakeholders in New York as well as other states for rational decision-making. In this 
review, data from the perceptions of stakeholders (including both medical personnel and 
parents of those infants with positive KD screens) as well as systematic cost analysis 
would provide important information to decision-makers faced with allocation of scarce 
resources. 
Purpose and Specific Aims  
The purpose of this study is to conduct a formal program evaluation of newborn 
screening for KD in New York State.  
The specific aims of this study are to assess:  
Aim One 
Stakeholder perceptions of the Krabbe Disease screening program in New York State. 
Aim Two 
The Krabbe disease test characteristics with the most recent data available.  
 	
 Aim	Three	






Newborn screening is a part of the preventative health system established in all states 
and territories of the United States. The system involves several components: screening, 
short-term follow-up, diagnosis, treatment/management, and evaluation. Each of these 
components has an underlying requirement for education and requires sufficient funding. 
The effectiveness of any screening program lies in the smooth integration of all 
components and careful attention to the ongoing evaluation of the screening program, 
including decisions made to add new tests. Decisions made by each state reflect 
differences in community values, state political and economic environments, and in 
public health technical capabilities (AAP Newborn Screening Task Force, 2000). Grosse 
and colleagues (2005) recommended that any policy decision regarding newborn 
screening, including assessment of benefits, interventions, risks and costs require 
evidence-based reviews to be available to the policy makers. Further, it is essential that 
the actual evaluative process be free from conflict of interest (Grosse, Boyle, Kenneson, 
Khoury, & Wilfond, 2005).  
In August of 2006, New York State was the first state to implement testing for 
KD. To date, this public health decision has not been formally evaluated. Published 
information regarding the cost of adding Krabbe disease to the newborn screening panel, 
from addition of the test to the panel to neurodiagnostic evaluation of those newborns 
with confirmed low enzyme activity is lacking. The proposed research will provide 




their newborn screening panel. 
Chapter II: Review of the Literature 
To provide the background for the development of the Krabbe disease (KD) 
screening program, the history of population screening, and the development of newborn 
screening were examined. A variety of evaluation frameworks and cost analysis strategies 
were examined to determine the method and framework for this study. In this chapter, the 
following topics are described in detail: population and newborn screening programs, 
KD, addition of KD to the New York state panel, methods for program evaluation, and 
cost analysis.  
History of Population and Newborn Screening Programs 
Research in Norway by AsbjØrn FØlling in the 1930s indicated that some 
mentally retarded individuals had very high levels of phenylpyruvic acid in their urine, 
called phenylketonuria (PKU) (Crowe, 2008). This acid was found only in people who 
lacked the enzyme to break down phenylalanine, an essential amino acid. High levels of 
phenylalanine in the body are toxic to the developing brain and cause mental retardation. 
By limiting the intake of phenylalanine in the siblings of these retarded individuals, 
FØlling was able to demonstrate that the siblings had better health outcomes.  Limiting 
phenylalanine was a concern, since restricting any essential amino acid may impair linear 
growth and can also cause mental retardation (2008). Therefore, a test that could 
accurately measure the amount of phenylalanine in the blood was needed. A call went out 
to scientists to develop a reliable test that could detect high serum levels before toxic 




phenylalanine and prevent any gross amino acid deficiencies.  
It wasn’t until the early 1960s that Dr. Robert Guthrie developed a simple test that 
could detect high levels of phenylalanine using blood collected on filter paper (Guthrie & 
Susi, 1963). Although the test was not specific and had many false positive results, it was 
easy to administer and provided information to guide medical practice.  
With a link between PKU and mental retardation clearly demonstrated, testing of 
all newborn infants was proposed to every state in the US. Massachusetts developed the 
first voluntary newborn screening program in 1962 to test newborn infants for PKU 
(AAP Newborn Screening Task Force, 2000). This program demonstrated that mass 
genetic screening was feasible, and other states slowly developed screening programs of 
their own. 
The adoption of the PKU screening by states was bolstered by the federal 
government sponsored public awareness campaign of the test. Additionally, a federal 
commission was developed to specifically explore causes of mental retardation (Lesser, 
1985). The President’s Panel on Mental Retardation was instrumental in providing 
sufficient information to support passage of Public Law 88-164, which provided funding 
to academic research centers (AAP Newborn Screening Task Force, 2000) to support 
scientific research in the study of rare diseases. This funding allowed scientists to develop 
other tests to add to existing newborn screening programs.  
In 1965, New York State followed Massachusetts and enacted Public Health Law 
2500a (New York State Newborn Screening Implementation Task Force, 2003), 




mandating the screening of newborns for inborn errors of metabolism, such as PKU, with 
state health departments having the role of implementing this legislation.  
 By the 1980’s, new techniques such as gas chromatography, enzymatic assays, 
and radioenzymatic assays had been developed and enabled detection of more inborn 
errors of metabolism. However, these new tests required plasma or urine instead of blood 
spots on a Guthrie card and were generally performed only on infants suspected of having 
an inborn error of metabolism. These methods were time-consuming, expensive, and 
required that technicians have highly specialized training for proper laboratory analysis 
of results (Chace, Kalas, & Naylor, 2003) and many states lacked sufficient resources to 
add these new tests to their screening panels. As a result, states adopted screening 
differentially, and these differences among programs were first reported by the American 
Academy of Pediatrics in 1999, raising awareness that variation in screening practices 
existed (AAP Newborn Screening Task Force, 2000). Today, over 4 million newborns 
are screened annually in the US for anywhere from 29 to 57 disorders depending on the 
state of birth (NNSGRC, 2010). This variation is controversial and experts and the public 
voiced outrage, arguing that a child could live or die depending upon the state in which 
he was born (Goldberg, 2000). 
Newborn screening today. 
In the 1990s, researchers at Duke University in North Carolina refined the use of 
the tandem mass spectrometer (Banta-Wright & Steiner, 2004). The development of mass 
spectrometry enabled dried blood spots collected in the nursery to be tested in an 




disorders were determined to be clinically significant. Due to the increased detection of 
inborn errors of metabolism, many more disorders were being detected in the newborn 
than had ever been diagnosed clinically (Wilcken, 2008). 
Of the disorders detected by mass spectrometry, half require a differential 
diagnosis, that is, one abnormal anylate can signify the presence of up to three disorders 
and further testing is needed to obtain a specific diagnosis. Furthermore, treating 
physicians began to recognize that many metabolic disorders had a spectrum of 
presentation, from no symptoms at all to classic presentation of severe illness. Without 
the ability to predict whether a disorder would become symptomatic, specialists were 
obligated to treat all infants as if they had disease, creating anxiety and hardship for many 
families (Waisbren et al., 2003). 
The concept of infants with a biochemical abnormality on newborn screening and 
no symptoms of disease has been described by Timmermans and Buchbinder (2010) as 
“patients-in-waiting.” Follow up of these patients-in-waiting has been cited as “the 
biggest challenge in newborn screening” (James & Levy, 2006, p. 253). 
As a result, today, a comprehensive newborn screening program includes the 
following: 1) screening of the newborn, 2) follow-up for referral of newborns that test 
positive for one or more diseases, 3) diagnosis or exclusion of a disease, 4) treatment and 
management of those with a confirmed diagnosis, and 5) program evaluation and quality 
assurance (Pass, 2000). Although the screening test alone appears simple, education and 
training is required for personnel at each point so a program may run efficiently, 




be considered when developing a newborn screening program, as each step of a program 
is dependent upon internal standards, skilled preparation of samples, and interpretation of 
results.  
Recognized as a valuable public health service, screening newborns is aimed at 
secondary prevention, providing early intervention or treatment to reduce mortality, 
morbidity, and other associated disabilities. With increasing ability to test for more 
disorders, it is important for decision-makers to have a set of guidelines available to assist 
in determining those tests that merit inclusion on a newborn screening panel. 
Guideline development for newborn screening programs. 
As population screening programs grew, national and international agencies 
began discussing the moral implications of these programs. Concerns were mainly 
regarding population screening in newborns for adult chronic conditions that had no 
effective treatment, such as Huntington’s disease. To address these concerns, various 
groups have developed principles to guide population screening (American College of 
Medical Genetics Task Force, 2006; Committee for the Study of Inborn Errors of 
Metabolism, 1975; National Institutes of Health, 1997; Therrell et al., 1992; Wilson & 
Junger, 1968). These guidelines are presented using a format similar to the National 
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 The first set of guidelines, written by Wilson and Junger, (1968) was relevant to 
newborn screening programs because they addressed the moral focus of the interests of 
the child, from the perspective of medical need and benefits to the newborn. These 
principles provided an underlying framework for the difficult task of adding new tests to 
screening panels as technology grew. These 1968 guidelines were seminal and cited in 
those that followed (Wilson & Junger, 1968). 
In 1975, the Committee for the Study of Inborn Errors of Metabolism of the 
National Academy of Sciences published a set of recommendations for genetic screening 
programs that suggested formation of a federal agency to provide oversight of genetic 
testing. This committee would have public representation and would review the 
feasibility, validity and use of new tests. The committee asserted that genetic screening 
tests should not be adopted without medical acceptance of new tests (Committee for the 
Study of Inborn Errors of Metabolism, 1975).  
In 1985, the Council of Regional Networks for Genetic Services was created to 
provide a forum for discussion among groups concerned with the public health aspects of 
newborn screening (Therrell et al., 1992). The council included representatives of state 
laboratories and administrators from each geographic region of the US. The council 
published guidelines in 1990 to specifically address newborn screening programs. The 
recommendations for adding or deleting tests from screening programs were that the 
process should be logical and systematic, and decisions should consider population 
demographics, methodology of testing, outcome of testing, and economics. Further, the 




accessible intervention. Scarce funding resources were addressed in these guidelines, 
suggesting that a uniform method of determining program costs should be developed 
nationally. 
The Task Force on Genetic Testing, funded by the National Institutes of Health, 
was created in 1995. This group published their report of suggested guidelines in 1997 
(National Institutes of Health, 1997). These guidelines for genetic testing were an attempt 
to address advancing technology by providing characteristics of tests identifying areas 
requiring stringent scrutiny by scientists, health care providers, and policy-makers. 
Although the task force encouraged development of tests for rare diseases, they advised 
caution regarding tests for conditions with no safe and effective clinical interventions. 
The committee placed emphasis on the importance of full informed consent for genetic 
testing, provided by the person administering the test. The task force also acknowledged 
the broadening scope of those who could be affected by genetic testing, from the 
asymptomatic infant, who could develop disease as an adult, to extended family 
members, to the ethnic group of the infant. The recommendation was to increase training 
and education of those providing genetic testing. This task force specifically 
recommended a formal charter for the Secretary’s Advisory Committee on Heritable 
Diseases of Newborns and Children to review the development and make 
recommendations for new screening tests for population screening programs. 
In 2000, based on the recommendations from the Task Force on Genetic Testing, 
the Maternal and Child Health Bureau Division of the Department of Health Resources 




Genetics (ACMG) to create a task force. This task force was asked to conduct a complete 
analysis of the scientific literature on the effectiveness of newborn screening, gather 
expert opinion to delineate the best evidence for screening specified conditions, and to 
develop recommendations focused on newborn screening, including the development of a 
uniform condition panel (ACMG Task Force, 2006). A survey was developed with 
scoring criteria in an attempt to create a ranking system for 84 disorders that were either 
currently in state newborn screening panels, or being considered for addition to existing 
panels.  The survey included 3 categories for each disorder: 1) clinical characteristics of 
the disorder; 2) analytical characteristics of the screening test; and 3) diagnosis, 
management and treatment of the disorder, which included both acute exacerbations and 
chronic care phases. Nineteen criteria for scoring were included within the 3 categories. 
This scoring system was developed to recognize the strengths and limitations of each 
condition and summarized them in a ranking system for a total of 2100 possible points.  
This way, a condition could have a low score in one category, but high in another 
category. However, this scoring system has been criticized as not conforming to 
contemporary evidence-based process, as well lacing transparency (Moyer, Calonge 
Teutsch, & Botkin, 2008),After a pilot study, the survey was distributed to newborn 
screening experts and advocates for their opinions. After analysis of the 300 responses, 
the disorders were divided into three groups: High scoring (1200-2100), Intermediate 
scoring (1000-1199) and low scoring (<1000). Conditions scoring below 1000 were not 
considered appropriate for screening, the conditions with scores >1200 were considered 




conditions were considered as secondary targets (ACMG Task Force, 2006). This 
resulted in a core panel of 29 disorders, with an additional 25 secondary target disorders 
that could be detected by differential diagnosis from the 29 core disorders. The American 
Medical Association published a report criticizing the survey criteria, the methodology of 
survey distribution used by the ACMG, and the lack of cost-effectiveness data to support 
the recommendations made by the group (American Medical Association, 2006). Another 
report published by the Hastings Center on behalf of the United States Preventive Service 
Task Force criticized the ACMG survey for not conforming to an evidence-based 
process, questioning the methodology used for evaluation of the conditions on the panel, 
and lack of consideration to the harms that a false positive screening result could cause 
when identifying infants who screen positive but have no symptoms of disease (Moyer,  
Colange, Teutsch, & Botkin, 2008). 
The ACMG survey criteria further broadened the rationale for newborn screening. 
Previous guidelines focused on testing for disorders to prevent death and disability in an 
affected child. The ACMG criteria defined benefits for the affected child to include 
burden of disease and potential for overall improvement with early intervention with or 
without a requirement for effective treatment (Grosse et al., 2005). Benefits to families 
were also expanded to include timely knowledge of a disorder to avoid the diagnostic 
difficulties accompanying many of the metabolic disorders. This benefit was given as 
much weight in the scoring system as prevention of mortality (Grosse et al., 2005).  
Despite differing opinions and criticism of the ACMG report, there was nearly 




experts in the field, and public policy decision makers (American Medical Association, 
2006) that standardized newborn screening criteria was needed. The ACMG uniform 
screening panel was adopted by the Secretary’s Advisory Committee on Heritable 
Diseases in Newborns and Children (Secretary's advisory committee on heritable 
disorders in newborns and children, 2009). This committee was chartered to evaluate new 
disorders nominated for addition to the uniform panel, perform an extensive evidence 
review, and to send recommendations to the Secretary of Health and Human Services 
(Green, et al., 2007).   
Reports submitted by this committee have provided evidence to Congress that 
facilitated passage of the Newborn Screening Saves Lives Act into Public Law 110-204 
in May 2008. The Newborn Screening Saves Lives Act was passed authorizing $45 
million each year in funding for education and outreach on newborn screening, to assist 
states in providing coordinated follow-up care after screening, and grant funds for 
purchasing necessary equipment to expand screening capabilities (Dodd, 2008). 
However, for fiscal years 2009 and 2010, this law received appropriation of just $10 
million per year in the Federal budget (Williams, 2009). While authorizing funding, no 
punitive language was included for states opting to test for more or less than the 
suggested 29 core disorders; thus, this law remains a guideline. 
 The ACMG guidelines (2006) added the criterion of economic evaluation when 
considering addition of a new test to a newborn screening panel. Despite the publication 
of many economic analyses of newborn screening programs, evidence of benefit has been 




been accepted as cost-effective; the expansion of existing screening panels may not be 
cost saving. Economic studies seldom fully address the issues of costs and consequences 
and the influence they may have on expansion of newborn screening panels (Grosse et 
al., 2005). The standard economic analyses also include decision parameters that fall 
short of consideration of all costs included in the incorporation of a new test into a 
screening panel (Hubbard, 2007). In this dissertation, efforts will be made to include the 
direct costs and consequences of KD screening from the perspective of the State. 
Overview of Krabbe Disease 
Krabbe disease (KD), also known as globoid-cell leukodystrophy, is an autosomal 
recessive disorder due to the deficiency of a lysosomal enzyme galactocerebrocidase 
(GALC), which results in failure of the myelination process of the central and peripheral 
nervous system. Incidence of KD has been estimated at 1 in 100,000 births in the US. 
First described in 1916 by Dr. Knud Krabbe (Krabbe, 1916), the classic disease (infantile 
form) causes rapid, progressive neurologic deterioration and death. Children who inherit 
the infantile form of the disease develop symptoms before 6 months of age. Symptoms 
include irritability, dysphagia, progressive spasticity, mental deterioration, blindness, 
deafness, and seizures. Children affected with infantile KD generally die before 2 years 
of age (Wenger et al., 2001). 
Two other forms of KD are known to exist, late infantile onset, which presents 
with symptoms after six months of age, and juvenile/adult onset, with symptoms 
appearing from four years of age to adulthood. All patients with KD have GALC activity 




resonance imaging (MRI), weakness, loss of motor skills, and may present with sudden 
onset of vision loss, and burning paresthesias of the extremities (Suzuki, 2003). However, 
the late infantile and juvenile/adult onset forms are highly variable in both disease 
symptom presentation and severity. This creates a diagnostic problem for the clinician, as 
the symptoms of KD also present in other neurologic conditions, like multiple sclerosis, 
other leukodystrophies and some ataxias (Arenson & Heydemann, 2005; Morse & 
Rosman, 2006; Srinivasan, Coleman, & Kornberg, 2008) . Thus, the possibility of KD is 
likely to be dismissed in favor of the more common diagnosis.  
Management and treatment of Krabbe disease. 
In the past, once KD was diagnosed, the only available option was symptom 
management until death occurred around two years of age. Experimental allogenic bone 
marrow transplantation had been published as treatment in case reports, but with little 
success in alleviation of symptoms (Krivit, Shapiro, & Peters, 1998). This treatment 
required an appropriately matched donor, which was often unavailable. Also, bone 
marrow transplant requires radiation to ablate the immune system, not an option for 
infants less than one year of age, since this could cause severe damage to a newborn’s 
brain. 
In 2000 the National Heart, Lung and Blood Institute of the National Institutes of 
Health sponsored a multi-center study to investigate the safety and feasibility of using 
partially matched, banked, unrelated donor umbilical cord blood stem cells for 
transplantation (UCBT) in children and adults with lysosomal storage diseases (Martin et 




study to evaluate UCBT for KD (Escolar et al., 2005). Twenty-five infants with infantile 
KD (11 asymptomatic newborns and 14 symptomatic infants) received UCBT after 
myeloablative chemotherapy instead of radiotherapy for ablation. The control group was 
a historical cohort of untreated patients obtained from a disease registry (n=190). The 
asymptomatic infants were siblings of children who had died from or had been diagnosed 
with KD. Endpoint measurements chosen were survival, donor-cell engraftment, and 
normal GALC levels. In the untreated historical cohort, all infants died by age 96 months. 
Over a 3-year average follow up period, all the asymptomatic children met every 
endpoint. Among the symptomatic recipients, 43% survived (6 out of 14) and of those 
who survived, 100 % had successful donor-cell engraftment. The infants in the 
asymptomatic group demonstrated improved neurologic and neurodevelopmental 
outcomes compared to the symptomatic group.  
Although the study results were favorable to those who received a transplant prior 
to onset of symptoms, ongoing issues requiring medical attention remained. Eleven of the 
25 children transplanted developed graft versus host disease, all of the children developed 
some degree of gross motor deficit, and all the children were below the fifth percentile in 
height and weight despite adequate nutrition (Escolar et al., 2005). 
While some benefits of early treatment have been documented, the data and 
treatment options are not clear-cut. Other than mentioning the number of children who 
developed graft versus host disease, the degree to which the transplant affects the infant 
and family has not been discussed. While gross motor development is mentioned as a 




growth retardation of all children receiving UCBT. Escolar, et al. (2009), reports that all 
the infants treated in the original UCBT treatment study develop some degree of motor 
function, ranging from mild to severe, but asserts their cognitive function is preserved. 
Additionally, controversy exists among the authors of the study done at Duke regarding 
the developmental components of the study. One author suggests the portrayal of 
developmental progress of the asymptomatic group is somewhat slanted, that these 
children appear obviously abnormal, and that cognitive delays will become more evident 
as these children entered school (Friedman, 2008).  
Duffner, et al (2009) published a summary of long-term outcomes of the children 
from the Duke study who were transplanted presymptomatically. The summary findings 
included the following: 1) the transplant procedure carries a 15 % mortality rate; 2) all 
the children slowly develop progressive neurologic deterioration over time, ranging from 
developmental delay, increasing spasticity, loss of motor milestones and language 
deficits; and 3) all had height and weight below the third percentile for sex and age 
(Duffner, Caviness et al., 2009). These issues point toward the lack of knowledge 
surrounding the natural course of the disease despite available treatment.  
Quality of life and cost have not been studied regarding the treatment and 
sequelae of treated KD. There is little information known about the late onset forms of 
the disease, or the outcomes of very low enzyme activity, which is currently being 
diagnosed because of newborn screening in New York State. The natural course of the 
later onset forms of KD is relatively unknown, and currently, the evidence regarding 




presented with information that is not comprehensive; therefore, more data are needed to 
better inform decision makers. 
Testing for Krabbe disease. 
Individuals with all forms of KD will have low GALC enzyme activity level (< 
0.15 nmol/h/mg protein) in leukocytes isolated from whole blood (Galvin-Parton, 2003).  
While the biochemical diagnosis of this disease is not difficult, due to the low incidence 
of the disease, as well as the belief among many clinicians that KD only presents in the 
severe infantile onset form, few clinicians consider this testing when neurological 
symptoms are present. Furthermore, symptoms of KD are similar to many more common 
neurologic disorders; thus, other diseases are often ruled out before specific testing is 
ever considered.  Measuring GALC enzyme activity provides only part of the diagnosis. 
To better predict the type of KD, an analysis of the genetic sequence should also be 
performed. 
The deoxyribonucleic acid (DNA) sequence for GALC was mapped in 1993 and 
is located on gene 14q31 (United States National Library of Medicine & National 
Institutes of Health, 2009). Currently, over 60 mutations are recognized to cause some 
decrease in activity, and the most common mutation causing infantile onset KD is a 
homozygous 30kb deletion (Suzuki, 2003).  Large deletions of the GALC gene are 
known to cause disease, but it remains unclear which combinations of mutations cause 
later onset disease. Unfortunately, the genotype is not indicative of disease severity, since 
family members having the same mutations may present phenotypically with very 





 In 2004, Li and colleagues presented the results of their multiplex screening 
model for five lysosomal storage diseases, including KD, using dried blood spots from 
newborn screening cards (Li, Brockmann, Turecek, Scott, & Gelb, 2004). By rehydrating 
the dried blood spot with a buffer solution containing substrates of the enzymes of 
interest, multiplex testing with tandem mass spectrometry was then possible.  
Testing for the GALC enzyme testing was 100% sensitive using this method (Li 
et al., 2004). However, problems arose with the specificity of the testing, such as overlap 
between the lsysosomal storage conditions, which then required further enzymatic testing 
to confirm a diagnosis. In practice, this further testing translates into increased technician 
time, and therefore, increased test cost. Problems were also reported with blood samples 
stored at temperature extremes resulting in false positive results, requiring increased time 
for personnel notifying parents of newborns, as well as increased confirmatory testing 
costs (Li et al., 2004). Another quality concern was that the research had been conducted 
using a relatively small number of samples. In this study, only 31 dried blood spot 
samples were processed manually over a period of days. There had been a concern that 
the much higher number of samples being processed in a newborn screening program 
could interfere with the accuracy of the test results (Li et al., 2004).  
New York State’s Wadsworth Laboratory processes approximately 500 dried 
blood spots daily, using an automated process. The technique described by Li et al. 
(2004) was not feasible to accommodate the volume of blood spots processed in New 




test for KD, and to increase throughput (Orsini et al., 2009). This modified technique was 
validated in a one-year pilot study conducted using 139,000 randomly collected, de-
identified newborn dried blood spot punches and dried blood spots of persons with KD as 
positive controls.  The method provided 100 % detection of all positive controls, as well 
as detection of one anonymous infant who was later diagnosed with KD. Based on these 
data, the cut-off value for a positive KD screen was also determined. 
Addition of Krabbe disease testing to the New York State panel. 
The impetus for inclusion of this test in the New York screening panel came from 
the KD advocacy group, Hunter’s Hope (www.huntershope.org). The spokesperson of 
this group was Jim Kelley, a former Buffalo Bills quarterback, whose son Hunter died of 
KD (Editors - Genomics & Genetics Weekly, 2004). The argument for adding KD to the 
New York State newborn screening panel was as follows: the results of the Duke study 
suggested favorable outcomes in presymptomatic infants treated with cord blood 
transplant, and a screening test was available that used the dried blood spots collected in 
the newborn nursery. Infants with KD could now be identified presymptomatically, so 
treatment could be pursued in a timely manner. Without screening, KD diagnosis was 
unlikely to occur until after symptoms had appeared. 
In January of 2005, Governor Pataki announced the decision to include KD 
screening to the New York newborn screening panel (Pataki, 2005). Prior to this decision, 
a scientific task force had been convened to review the evidence from the then 
unpublished Duke treatment study, the results of pilot testing in New York using the 




inclusion of the KD on the panel. The task force was comprised of metabolic specialists, 
genetic specialists, neurologists, and pediatricians, all from New York State, who 
unanimously recommended against inclusion of the test on the panel (Pacenza, 2006).  
Despite the task force recommendation and prior to any published evidence regarding 
treatment, on January 18, 2006, section 69-1.2 of NYCRR 10 of Public Health Law 
§2500-a, was amended by emergency rule. The finding of necessity provided in the 
Emergency Rule legislation to add Krabbe disease to the newborn screening panel was, 
“Preservation of public health,” (Expansion of the New York State newborn screening 
panel, 2006. p.6). Under the heading of Alternative Approaches on page 9 of the New 
York State Register, February 8, 2006, it is stated:  
Potential delays in detection of Krabbe disease until onset of clinical symptoms 
would result in increased infant morbidity and mortality, and are therefore 
unacceptable. Given the strong indication that treatment is available to ameliorate 
adverse clinical outcomes in affected infants, the Department has determined that 
there are no alternatives to requiring newborn screening for this condition. (p. 9) 
It remains unclear whether the decision to include KD to the New York screening 
panel meets the goal of preventing irreversible neurological damage or developmental 
delay as stated by the New York State Newborn Screening Task Force (2003). 
Nonetheless, inclusion of the test by New York State has been cited as evidence to 
support its inclusion on other state newborn screening panels. To date, Illinois, Missouri, 
and New Mexico have added KD screening to their newborn screening panels, based in 




set to be expanded, 2009; Associated Press, 2010). 
Recently, after review of existing evidence, three years after New York added KD 
to the newborn screening panel, the Secretary’s Advisory Committee for Heritable 
Disorders of Newborns and Children recommended not adding KD to the core panel of 
newborn screening tests (Howell, 2009). The rationale provided for this conclusion was 
insufficient evidence in several areas: the impact of a positive screen on families, 
diagnostic difficulty in identifying affected infants, and issues regarding treatment 
outcomes (Kemper et al., 2010). A systematic program evaluation is the first step to 
provide information needed to better inform decision-makers both in New York as well 
as other states and countries. 
Overview of Krabbe disease screening in New York State. 
When the New York State Health Department implemented KD screening, it was 
estimated that 25 newborns would be referred annually for confirmatory testing of the 
severe infantile onset form of the disease, and 3 would be confirmed with disease (New 
York State Department of Health, 2003). The later onset forms of the disease, while 
known, were thought to be so rare that no consideration to their detection was given. In 
practice, however, more infants have been identified with very low enzyme activity and 
no symptoms of disease than infants with the early onset form of KD (Duffner, 2010). 
Counseling families of these infants may be problematic for the metabolic 
specialists, as little is known about the onset, natural history, or treatment of later onset 
forms of KD. Parents of newborns diagnosed with very low enzyme activity may be left 




may increase use of health care resources even when their child appears completely 
healthy (Waisbren et al., 2003). These families are left with diagnostic uncertainty and 
may be unclear about whether or not their child will develop KD or unsure if their child 
even has a disease (Timmermans & Buchbinder, 2010). Therefore, the criteria of 
“effective, available treatment, and adequate understanding of the natural history of the 
condition, including development from latent to declared disease,” set by Wilson and 
Junger (1968) becomes an area of controversy regarding the inclusion of this disease in 
newborn screening panels. This dissertation addresses the gaps in the literature by 
assessing the perceptions of the KD screening program from the perspective of both the 
parents and medical specialists.  
After KD was added to the New York newborn screening panel, a consortium was 
formed to implement screening and review the progress of the program. The rationale for 
the formation of the consortium was the different method of confirmatory testing and the 
irreversible and more dangerous treatment required for KD compared to other inborn 
errors of metabolism on the panel. The Krabbe Disease Consortium is a multidisciplinary 
group consisting of neurologists, metabolic specialists, hematologists, nurse practitioners, 
genetic counselors and laboratory scientists directly involved with newborn screening in 
New York State. The consortium is funded by the Hunter’s Hope Foundation (Duffner, 
2008), the nonprofit arm of the parent advocacy group. The Krabbe Disease Consortium 
has met every six to eight months since KD screening was legislated to address issues 
arising from testing (2008). As pediatric nurse practitioner at the Mount Sinai Medical 




There have been several changes in the KD program as a result of these meetings, 
notably the use of a single confirmatory enzyme testing lab, reconsideration of  the “low 
risk to develop disease” category, and minor changes in the follow up protocol (Duffner, 
2010). While minutes are taken during these meetings, they have not been reliably 
distributed (J. Pelligrino, J. Kwon, G. Arnold, personal communication, April 16, 2010) 
A clinical protocol was developed by consensus of the consortium to provide 
ongoing evaluation of children who had confirmed low enzyme activity (Appendix 2). 
This clinical protocol was developed using expert opinion to provide a more standardized 
approach for further evaluation and determination of recommendation for transplant. 
However, the protocol has not been validated, and is not adhered to consistently in the 
eight specialized care centers, often due to parental refusal of the invasive tests (Duffner, 
2010).  
 A point system based on the results of the activities in the protocol was also 
established to guide referral for UCBT. The follow up protocol and point system are 
found in Appendix 2. However, there is disagreement regarding the actual effectiveness 
of the treatment (Friedman, 2008). Furthermore, UCBT is invasive, irreversible, and the 
associated mortality rate is high. The long-term effects of UCBT for the early onset form 
of the disease have not been sufficiently studied, and questions remain about the true 
effectiveness of the only available treatment.  
Detailed description: Krabbe disease screening program and goals. 
To provide a detailed description and understand the goals of the KD Screening 




The documents providing the data for content analysis came from several sources, 
including: written and electronic publications from Wadsworth Laboratory for the public, 
health care providers, and other laboratories; New York State Public Health Law §2500-
a; minutes from the KD consortium meetings; the emergency rule proceedings published 
in February 2006; other published descriptions of the New York State KD screening, and 
testing methods. All documents were entered into the NVIVO 8 ® (QSR International 
Pty Limited, 2008) software program for data storage and content analysis. What follows 
is a synthesized description of the New York State KD screening program and 
programmatic goals. 
All infants born in New York are screened for 46 disorders 24 hours after birth 
(New York State Department of Health, 2006b). The aim of this screening according to 
the State Legislature is to identify New York’s youngest citizens with serious, but 
treatable neonatal conditions and assure timely referral for medical intervention 
(Expansion of the New York State newborn screening panel, 2006). Screening is 
mandatory; however, a parent may choose to opt out of screening based on religious 
objection (Testing for phenylketonuria and other diseases and conditions, 1997). 
Providers are required to notify parents that the screening is being done and provide 
education about the screening to the parents. To meet this requirement, a pamphlet is 
available explaining the screening in English, Spanish, French, Haitian Creole, Chinese, 
Russian, and Vietnamese (New York State Department of Health, 2006b). Blood is 
collected via heelstick in the nursery, placed on a Guthrie card, dried, and sent to 




Screening Implementation Task Force, 2003).  
At the Wadsworth Laboratory, the dried blood spot punches are processed using 3 
different methods. For KD, tandem mass spectrometry is used to identify the GALC 
activity (New York State Department of Health, 2003). The value chosen for a positive 
screen was the average percentage of daily mean activity of GALC over 3-day period. 
The cutoff point determination for a positive screen for KD was set conservatively to 
minimize the potential for false negative results. If the GALC activity is ≤ 12%, a 
secondary analysis is performed. This secondary analysis looks for mutations and 
polymorphisms associated with KD, and was instituted to reduce the number of false 
positive results (Orsini et al., 2009). The screening algorithm for KD is shown in figure 1 
and is discussed below. 
Figure 1 
Krabbe Disease Screening Algorithm 
 




When an infant screens positive for KD, either the infant’s pediatrician of record 
or a representative from the metabolic referral center notifies the parents and an 
appointment is made for confirmatory testing. At the metabolic center, the infant receives 
a full physical examination, and an explanation of genetic inheritance, mutations, and KD 
is provided to the family. Five milliliters of blood is collected from the infant and sent for 
confirmatory enzyme activity at the Lysosomal Diseases Testing Laboratory at Thomas 
Jefferson University in Philadelphia, PA (New York State Department of Health, 2003). 
After signing informed consent for genetic testing, blood spots are collected from both 
parents and the infant and sent to Wadsworth laboratory for deoxyribonucleic acid 
(DNA) testing of the GALC sequence and to assure correct identity of the infant. Enzyme 
activity results are available in 3 days and the parents are contacted with the results. DNA 
results are provided at a later date to the metabolic specialist by Wadsworth laboratory, 
and parents are informed of their results by the metabolic center. 
If the confirmatory enzyme activity is less than 0.3 nmol/mg protein/hour, the 
infant is admitted to the hospital for a neurology evaluation, lumbar puncture, magnetic 
resonance imaging (MRI) with sedation, visual evoked potential (VEP), and a nerve 
conduction velocity test (with F-wave) (Duffner et al., 2009). If the infant’s DNA 
sequence reveals two 30kb deletion mutations, or the enzyme activity is less than 0.15 
nmol/hr/mg protein, a consultation with an oncologist for UCBT evaluation is ordered, 
and human leukocyte antigen (HLA) typing is conducted for the infant and both parents 
(New York State Department of Health, 2003). At this point, parents are informed about 




From the perspective of the State, the goal of newborn screening in New York is 
found on the Wadsworth Laboratory website, as well as in the Guide for Health 
Professionals (2003). The goal is stated:  
The goal of newborn screening is early identification of children at increased risk 
for selected metabolic or genetic diseases so that medical treatment can be 
promptly initiated to avert metabolic crises and prevent irreversible neurological 
and developmental sequelae. (p.1-1) 
 In the educational pamphlet provided to parents (New York State Department of 
Health, 2006b), the goal of newborn screening is stated in a slightly different manner. 
The goal is, “To help ensure that your baby will be as healthy as possible,” and further 
asserts, “With early diagnosis and medical treatment, serious illness can often be 
prevented.” (para 1) 
Overview of Program Evaluation 
Evaluation is the systematic investigation of a product or activity to determine its 
merit (quality), worth (cost-effectiveness), and significance (importance). When applied 
to organized activities intended to promote and protect health, an evaluation usually 
determines whether specified "outcomes" or health goals were reached and whether or 
not those results can be attributed to the program (Center for Health Improvement, 2008). 
Evidence based program analysis is grounded on the availability and accessibility of 
information and how context affects the evidence used (Dobrow, Goel, & Upshur, 2004). 




results. A number of evaluation frameworks were reviewed to determine relevance for 
this study (Center for Health Improvement, 2008; Centers for Disease Control and 
Prevention, 1999; Stufflebeam, 2003).  
In 1977, the Centers for Disease Control and Prevention (CDC) convened a 
working group to develop a framework that could be used to provide a comprehensive 
and systematic evaluation method for public health programs. In the development of this 
framework, existing evaluation frameworks were reviewed. The result of this 
workgroup’s efforts was the CDC Framework for Evaluation of Public Health Programs 
(1999). The framework is depicted graphically in figure 2. 
Figure 2: CDC raeor for Prora valation in Pli ealt 









specifically a public health program, making it ideal for evaluating the addition of KD 
screening to the New York State newborn screening panel. Standards are placed in the 
center of the framework graphic to represent their application throughout the entire 
evaluation. They provide the investigator with guidelines to assure a thorough and 
balanced evaluation. Standards of program evaluation are used to answer the question, 
“Will this evaluation be effective?” (Milstein & Wetterhall, 1999). The standard of utility 
ensures the information collected during the evaluation will be valuable and timely. 
Feasibility represents the practicality of the evaluation, that it is conducted in a 
nondisruptive and frugal manner.  Propriety standards ensure that the evaluation is 
conducted in a legal, ethical manner, with regard to the rights of those who participate in 
the process. Finally, the standard of accuracy promotes the transparency of methods, data 
collection and reporting of accurate information. 
For each of the six steps, suggested activities and evaluation techniques are 
defined in a systematic, evidence-based fashion. The use of several methodologies is 
recommended to complete each of the steps, resulting in a thorough, systematic 
evaluation. Integration of qualitative and quantitative information has been thought to 
increase the likelihood that evidence will be balanced (Centers for Disease Control and 
Prevention, 1999).  
An important part of this evaluation framework involves engagement of the 
stakeholders. Stakeholders are chosen to represent the groups recommended by the 
authors of the CDC Framework (1999). These recommended stakeholder groups are: 1) 




3) Those in a position to make decisions about the program. The third group of 
stakeholders generally includes legislators, and may also include stakeholders from the 
other two groups, if they have input into the decision making process.  
As outlined by the framework, a complete program description includes: the need 
for the program, the context within which the program operates, explanation of program 
activities, and description of resources. The description provides a synthesis of the main 
program elements to display how the program is supposed to work and the intentions, 
focus, or communication trends of any individuals, groups, or institutions involved with 
the program. The detailed description of the program was conducted as preliminary work 
in the development of this dissertation and was reviewed earlier in this chapter.   
To focus the evaluation design, a thorough description of the methodology and 
rationale for choosing a particular method must be provided. The choice of methodology 
and process of data analysis drives the collection of credible evidence. The methods 
chosen for this dissertation are discussed in Chapter 3.   
 The ACMG guidelines (2006) added the criterion of economic evaluation when 
considering addition of a new test to a newborn screening panel. Despite the publication 
of many economic analyses of newborn screening programs, evidence of benefit has been 
debated. Grosse (2004) asserts that while newborn screening programs have certainly 
been accepted as cost-effective; the expansion of existing screening panels may not be 
cost saving. Economic studies seldom fully address the issues of costs and consequences 
and the influence they may have on expansion of newborn screening panels (Grosse et 




short of consideration of all costs included in the incorporation of a new test into a 
screening panel (Hubbard, 2006). Cost studies are one way to evaluate the value of 
adding tests to newborn screening panels. In this dissertation, efforts will be made to 
include the direct costs and consequences of KD screening from the perspective of the 
State. 
 The interpretation of the data must be adequately explained. The results of the 
analysis are presented in Chapter 4 and then discussed in Chapter 5. The framework 
recommends that the process should be transparent and lead to conclusions and 
recommendations that are useful to the stakeholder groups.  
The last step of the evaluation is to ensure its use. To accomplish this, conclusions 
will be made available to stakeholders and to the public by presentation at national 
meetings and publication of the evaluation in academic journals. The dissemination to 
date and future plans are discussed in Chapter 5. 
The CDC Framework provides the basis for this evaluation of the KD screening 
program addition to New York State’s newborn screening panel. Compared to other 
evaluation methods, this framework is comprehensive and systematic, as well as focused 
toward public health programs. 
Summary 
The addition of screening for KD to the New York State newborn screening panel 
in 2006 has not been formally evaluated in a systematic way. This is problematic, given 
that other states have added or are considering addition of this screening test based only 




found regarding Krabbe screening effectiveness or the costs involved with the addition of 
the screening to the established screening panel. No published information exists for 
decision makers in other states to consider when deciding on utilization of already scarce 






















Chapter III: Design and Methodology 
The aims of the study were to assess: 1) stakeholder perceptions of the Krabbe 
Disease screening program in New York State, 2) the KD test characteristics with the 
most recent data available, and 3) the actual costs of the KD screening program. The data 
sources, data collection sites, and methodology for each study aim will be discussed in 
detail in this chapter. Briefly, a mixed methodology using the qualitative techniques of 
semi-structured interviewing, constant comparison and thematic content analysis and 
quantitative techniques of calculating test result characteristics and a simple cost analysis 
was conducted to provide a rich evaluation of the KD screening program. 
Study Design – Guiding Framework 
To fully evaluate KD as the most recent addition to the New York State newborn 
screening program, a formal, systematic program evaluation was performed. The 
Framework for Program Evaluation in Public Health developed by the CDC (Milstein & 
Wetterhall, 1999) discussed in Chapter 2, was used to guide the research. The steps and 
standards are described in figure 3, which has been adapted to reflect their specific 










Figure 3: CDC framework steps and standards for effective evaluation 
 
Steps in Evaluation  
 
Step 1: Engage stakeholders 
 -Persons involved in the program – Health Care Providers, Program directors 
-Persons affected by the program – Parents 
            -Program decision-makers– Program directors, Legislators 
Step 2: Describe the program 
 -Chapter 2 - Review of the Literature 
 -Chapter 2 - Description of Krabbe Disease Screening and Program Goals 
Step 3: Focus the evaluation design 
 -Chapter 3 - Design and Methodology 
Step 4: Gather credible evidence 
 -Chapter 3 - Design and Methodology 
 -Chapter 4 - Results 
Step 5: Justify conclusions 
 -Chapter 4 - Results 
 -Chapter 5 - Discussion 
Step 6: Ensure use and share lessons learned 
 -Poster presentations at national meetings  
 -Dissertation Defense 
 -Distribution of findings to study participants 
 -Publication in academic journals 
 
Standards for Effective Evaluation 
 
Utility:  
- The need exists for an objective, formal program evaluation of the decision to add Krabbe 
disease screening to the NYS newborn screening panel. 
-Krabbe disease was not recommended for addition to the core panel of conditions for newborn 
screening in 2009 due to lack of supporting evidence.  
Feasibility:  
-The timeline for data collection was estimated at 1 year. 
-Funding obtained from a grant awarded by Sigma Theta Tau – Alpha Zeta Chapter  
Propriety:  
-Investigator completed training in Human Subjects Research Protection 
-Study approved by the Columbia University Institutional Review Board 
-All participants signed informed consent prior to study participation. 
Accuracy:  
-All sources are documented. 
-Audit trail of data collection and analysis available.  
 





Overview of Aims and Methods 
A brief overview of the aims, analytic methods, and data sources is presented in 
Table 2. This is followed by the detailed descriptions of the methodology for each aim. 
Table 2 
Design and Methods of Krabbe Disease Program Evaluation 
 
Study Aim Method Data Sources 
Stakeholder perceptions of 
the Krabbe Disease 
screening program in New 
York State. 
 
Qualitative thematic analysis 
to analyze interviews of each 
stakeholder group 
 
 Semi-structured interviews 
using interview guides based 
on programmatic goals 
 State laboratory officials 
 Medical directors of 
designated Specialized care 
centers 
 Representative of Hunter’s 
Hope Parent Advocacy group 
 Parents of infants who 
screened positive for Krabbe 
disease 
Assess the Krabbe disease 
test characteristics with the 




specificity, positive predictive 
value, negative predictive 
value, and prevalence 
 Public records of test results 
from August 2006-July 2010 
 Krabbe Consortium meeting 
minutes 
 Director of confirmatory 
testing laboratory 
Assess the actual costs of 
the Krabbe disease 
screening program. 
 
Cost identification analysis to 
calculate the cost of Krabbe 
disease screening from the 
perspective of the State 
 Cost and charge data from 
confirmatory testing 
laboratory 
 Cost and charge data from 
selected  
specialized care centers 
 Cost information from 
Wadsworth Laboratory 
 Calculated test 
characteristics from Aim 2 




Data Collection and Analysis - Aim 1  
To assess stakeholder perceptions of the Krabbe Disease screening program in New 
York State. 
Data collection sites. 
Data were collected from several sites in New York State. The sites included the 
Wadsworth Laboratory in the Department of Public Health located in Albany, NY, which 
is the laboratory that performs the newborn screening for the entire state. Medical 
stakeholders at all eight specialized care centers for inherited metabolic disease located 
across New York State were contacted. These specialized care centers are designated 
under Article 28 of the Public Health Law§2500-a as health care facilities that can 
provide treatment and/or services to children identified by the newborn screening 
laboratory (New York State Newborn Screening Implementation Task Force, 2003). 
Finally, data were also collected from the Lysosomal Disease Testing Laboratory at 
Jefferson University in Philadelphia, Pennsylvania, which performs the confirmatory 
testing for the infants that screen positive for KD. 
Sample description. 
The sample selection for each stakeholder group was purposive, using a criterion 
strategy described by Miles and Huberman (1994). This strategy includes selecting 
participants who had a specific role in the criterion under study and is one technique used 
to ensure transferability of results. Purposive sampling was used to choose participants 
who had experience within the KD screening program. Using the CDC Framework as a 




of specific stakeholder groups, which is the criterion for participation. Table 3 provides a 
description of the total population available for this study for each stakeholder group. 
Table 3 
Sample Description Table 
Stakeholder group Description Total population
 Governor of New York State 1 
 Commissioner of Public Health 1 




Those in a position to make 
decisions about the program 




Director of Wadsworth Laboratory 
 
1 
Director of Metabolic Disorders 
 
1 
Director of Confirmatory Testing 
Laboratory 
1 
Medical directors and neurologists at 





Those served or affected by 
the program 
Representative of Hunter’s Hope 
parent advocacy group 
1 
Parents of infants screened positive 
for Krabbe disease meeting inclusion 
criteria 
154 
Total  177 
 
The largest population of the stakeholders is represented by the parents of infants 
who have screened positive for KD since inception of the program. As of July 2010, 185 
infants screened positive and were referred for confirmatory enzyme testing (Duffner, 
2010). It was not feasible or necessary to interview parents of all infants who screened 
positive, so the following inclusion criteria were developed for participation in this study: 




prior to the interview, and 3) willingness to allow audio recording of the interview. After 
these criteria were applied, a total of 154 parent stakeholders were identified for 
recruitment and total of 23 medical, legislative, and program director stakeholders were 
identified.  
Recruitment and retention. 
To engage the stakeholder groups in study participation, a short abstract was 
developed describing the aims and significance of the proposed research and provided to 
the identified stakeholders (see Appendix 4). Parents of infants who screened positive for 
KD received this information from their evaluating specialized care center. Those 
interested in study participation returned a stamped, pre-addressed postcard to the 
investigator. Following receipt of the postcard, the investigator contacted the parent to 
schedule an interview. Medical personnel were contacted directly by the investigator. 
Recruitment was planned until thematic saturation was achieved. Generally, this occurs 
following completion of 10 to15 interviews (Strauss & Corbin, 1998). 
 Interview guides.  
 Based on the synthesized description and programmatic goals, initial interview 
guides for each of the stakeholder groups were developed (Appendix 5). Guides varied 
slightly depending on the program goals and descriptions for each of the stakeholder 
groups. To assess for bias and content, the dissertation advisor evaluated the interview 
guides prior to use. These guides provided a framework for the investigator, but were 
neither rigid nor inclusive. The semi-structured format allowed flexibility, and the guides 




interviews progressed, using the process of constant iteration. This process is described 
by Creswell (1998), as a zigzag, consisting of gathering data, analyzing data, and then 
returning to the field to collect new information using the previous data to guide the 
collection. The guides used in the last interviews are found in Appendix 6.  
Interview procedure. 
The student investigator conducted face to face interviews with medical 
participants at six of the eight specialized care centers, the Wadsworth Laboratory, and 
the confirmatory testing laboratory in Philadelphia, PA. Parent participant interviews 
were conducted in their homes or other location of their choice. Four interviews were 
conducted by telephone for participant convenience.  
All interviews were audio recorded using a digital recording device. A back-up 
device was available in case of device failure. Field notes were taken during the interview 
to add context and clarity to the subsequent transcriptions. Interviews lasted 
approximately one hour. 
Human subjects protection. 
Aim 1 was the only aim that required active human subject participation. The 
Columbia University Medical Center Institutional Review Board approved all study 
procedures (see Appendix 4 for copy of IRB certificate and stamped informed consent). 
All participants provided signed informed consent prior to being interviewed. 
Data analysis - Aim 1. 
The qualitative method of emergent content analysis was used to analyze the data. 




to emerge from the data to better understand how stakeholders perceive the process under 
study (Hsieh & Shannon, 2005). This is an iterative process, consisting of six steps 
described by Johnson and LaMontagne (1993). These steps are: 1) Preparation of the 
data, including transcription of the audiotaped interviews; 2) thorough familiarity of the 
data through multiple readings of the transcripts and by listening carefully to the taped 
interviews; 3) identification of units of analysis by bracketing; 4) initial designation of 
codes; 5) refinement of codes into categories; and 6) establishing major contextual 
themes from the categories. By adhering to an analytic process, the validity and 
trustworthiness of the study is increased (Hsieh & Shannon, 2005). In this section, 
examples are provided for each of the steps of this process. 
To prepare the data, after each interview was completed, the recorded interviews 
were transcribed by a transcriptionist and reviewed for accuracy by the investigator. All 
interview recordings and transcripts were assigned initials and numbers to assure 
participant confidentiality. The following initials were assigned to each participant 
category: Program directors (D), medical personnel (M), and parents (P). Numbers were 
assigned sequentially, in the order of the interviews.  
Based on work done by Barbour, et al. (2000) each one-hour interview was 
predicted to take 2 to 4 hours to transcribe and an additional 20 hours to analyze. 
Transcripts and field notes were managed using the NVIVO 8® (2008) qualitative 
research software program, which also provided an audit trail as the qualitative analysis 
progressed.  




interview, every transcript was reviewed, and initial codes were assigned to the interview 
text, identifying topics and phenomena of interest. Transcripts were reviewed in an 
ongoing fashion to uncover similarities, focusing on the manifest content of the 
interviews using a constant comparative approach. Manifest content is defined as the 
visible, obvious components of what is said (Graneheim & Lundman, 2004). This basic 
coding process is a method used to organize large quantities of text into much fewer 
categories that describe the content of what is being said (Weber, 1990). This was done 
by reading each transcript in entirety, then rereading and highlighting text and phrases 
that captured the meaning of what the participant was saying. A code was assigned to this 
highlighted text by the investigator. After two interviews had been coded, these codes 
were used to identify similar text and phrases in the following interview texts, adding 
new codes when data did not fit into any of the existing codes. This continued throughout 
the data collection process. 
To refine the codes into categories, the transcripts were reviewed again, beginning 
with the third interview, and codes were grouped as similarities were identified. The 
categories served to illustrate the stakeholders’ understanding of KD testing relating to 
both the program goals and their experience of the process. Categories were reviewed and 
revised throughout the process of data collection, and some categories were eliminated, 
as the codes were found to fit better in other categories.  
Constant comparative analysis of the data between interviews, that is, comparing 
the content of each interview to the others (Glasser & Strauss, 1967), was conducted to 




the categories (Miles & Huberman, 1994) and a definition of the theme was developed to 
capture the overarching concept. The technique of constant comparative analysis also 
aids in the assessment of theoretical saturation, the point at which collecting data yields 
no new information (Strauss & Corbin, 1998, p.136).  
Data Collection and Analysis - Aim 2 
Assess the KD test characteristics with the most recent data available. 
The data sources for Aim 2 were the newborn screening results of New York 
State collected from August 2006 until July 2010. These publicly available annual reports 
included those infants who screened positive for KD and those with no disease, and are 
found on the Wadsworth Center website (Wadsworth Laboratory, 2009). Confirmatory 
test results and disposition of children with positive results were obtained from the 
meeting minutes of the Krabbe Consortium (Duffner, 2010). 
Test characteristics assessed for Aim 2 were sensitivity, specificity, positive 
predictive value and negative predictive value. These characteristics are commonly used 
to evaluate the performance of a screening test (Sahai & Marsden, 2009). Sensitivity is 
defined as the probability of a positive test given the presence of the target disease. 
Specificity is defined as the proportion of patients who do not have the target disease and 
who screened negative (Strauss, Richardson, Glasziou, & Haynes, 2005). The positive 
predictive value represents the precision of the test, in other words, the likelihood that a 
patient with a positive screen actually has KD. The negative predictive value represents 
the accuracy of the test, or whether the initial screening test correctly identifies those 




Prevalence was also calculated and describes the number of people with a disease in a 
given population within a specified time frame. Table 4 is the contingency table 
representing the calculations used. 
 
Table 4 
Contingency table to assess KD test characteristics 
 
Newborn Screen (DBS) 
 
 










































a  + c 
 
b + d 
 
a + b + c + d 
 
Note:  DBS – dried blood spot 
 GALC - galactocerebrocidase 
Sensitivity = a / (a + c) 
Specificity = d / (d + b) 
Positive Predictive value = a / (a + b)  
Negative Predictive value = d / (c +d) 
Prevalence = (a+c) / (a+b+c+d) 
 
In the case of KD, newborn screen results from the dried blood spots and 
confirmatory enzyme results from a venipuncture are not represented in the same units of 
measurement. Table 5 provides the units of measurement for both positive and negative 
test newborn screening results and confirmatory enzyme results presented in the same 





Krabbe disease testing defining characteristics 
 
Newborn Screen Testing  









No Risk  
(negative) 
GALC ≤0.15  
nmol/hr/mg protein 
 + mutations 
GALC > 0.16 
nmol/hr/mg protein 
(may have mutations) 
Negative Screen  
> 12% activity 
False Negative 
(later develop KD) 
True Negative 
(never develop KD) 
 
Note: GALC – galactocerebrocidase 
KD – Krabbe disease 
 
 
In newborn screening, it would be ideal to have a test with a sensitivity, 
specificity, and positive predictive value of 100% and a false positive rate of 0 (Sahai & 
Marsden, 2009). For the disorders on newborn screening panels, the cut-off points for 
reporting are set high in an attempt to eliminate false negative results, with the 
understanding there will be many false positive screens. To compensate for the expected 
number of false positives, the confirmatory test for the disorder should have a high 
positive predictive value to assure prompt treatment initiation, and avert morbidity or 
mortality. Since the positive predictive value is affected by the prevalence of a disorder, 
and all the disorders on newborn screening panels are rare, the expected positive 




Collection and Analysis - Aim 3 
Assess the actual costs of the Krabbe disease screening program.  
A simple cost analysis was conducted using the costs associated with the KD 
screening program. This type of analysis measures the cost of a program, and was chosen 
because there were no published data regarding the costs associated with KD screening; 
confirmatory testing, neurologic consultation and neurodiagnostic work up. 
To obtain a range of estimates, cost and charge data were collected from a variety 
of sources, including: the New York State Medicaid Physician Fee Schedule 2010 (New 
York State Department of Health, 2010), Mount Sinai Charges (Mount Sinai Medical 
Center, 2010), United Health Care Consumer Cost data (United health care treatment cost 
estimator, 2011), and Strong Memorial Hospital costs from Rochester, NY (Kwon, 2007). 
These sources were chosen to represent urban areas, rural areas, insured and uninsured 
financial data.  
The cost categories displayed in Table 6 represent the office visits and procedures 
infants undergo after a positive newborn screen for KD and after a positive confirmatory 
enzyme test based on the consensus protocol used in New York State (Duffner et al., 
2009). The cost categories are displayed using the Current Procedure Terminology II 
(CPT II®) codes (American Medical Association, 2009) used for billing and the 
International Statistical Classification of Diseases (ICD-9) codes (International statistical 












screen for Krabbe 
disease 






New patient consult 
(Metabolic) 
99205 796.6 
Venipuncture < 3 yrs 36400 796.6 









New patient consult 
(Neurology) 
99205 330 
Lumbar puncture & analysis 
(inpatient) 
62270 330 
Nerve conduction velocity 
w/F-wave 
95903 330 
Brainstem auditory evoked 
response 
92585 330 
MRI Brain w/wo contrast 70553 330 
Hospital admission – 
pediatric 
99357 330 
Anesthesia for MRI 99148 330 
 
Note: 796.6 – Abnormal Findings on Newborn Screen 
          330 – Leukodystrophy-NOS 
 
Every effort was made to use cost-accounting data instead of actual charges to 
reflect a more realistic reporting of the costs involved with the procedures in this study. 
Those costs that were reported in another year’s currency were converted to 2010 US 
dollars by using the cost conversion factor calculator found on the Bureau of Labor 
Statistics web page (www.bls.gov/guide/geography/inflation.htm). This calculator 
included geographic variation specific to New York State. Charge data from Mount Sinai 
Medical Center were converted to costs using the typical hospital cost to charge ratio 
conversion of 0.39 (Medi-cost.com, 2011). 




for cost data was from the time of initial blood collection in the newborn nursery to the 
time of neurologic evaluation and neurodiagnostic workup for a positive confirmatory 
enzyme test. Using the protocol established by the Krabbe Consortium of New York, this 
horizon is 2 weeks. Because of the short time frame, discounting is not applicable. The 
total cost of the program was then calculated for the period of time from August 2006 
through July 2010 based on the total number of positive results from Aim 2. The analysis 
was based on best point estimates available.  
Assumptions made in this analysis are that all newborn screening is performed 
according to the written protocol from the Wadsworth Laboratory and confirmatory 
testing and procedures are performed according to the written protocol developed by the 
Krabbe Disease Consortium (Appendix 2). There is no distinction made between the 
infants with early infantile Krabbe disease and the group of infants with very low enzyme 
activity and mutations consistent with later onset Krabbe disease after confirmatory 
testing. The rationale for this decision is that both groups initially undergo the same 
procedures as outlined in Table 6.  
Only direct medical care costs were included in this analysis. Direct nonmedical 
costs such as parent absence from work and travel time were included in probing 
questioning during the qualitative interviews. However, the formal cost identification 
analysis did not include these costs. Other indirect costs, such as staff time and postage 






Chapter IV: Results 
In this chapter, the results of the study are presented in detail for each of the three 
study aims. Each aim will be repeated for the reader’s convenience.  
Aim 1 
To assess stakeholder perceptions of the Krabbe Disease screening program in New 
York State. 
 To gain the perspective of stakeholders regarding the addition of KD screening to 
the newborn screening panel, a total of 22 in-depth interviews were conducted. After 
informed consent was signed, 18 interviews were conducted face-to-face and four were 
conducted by telephone. For this study, theoretical saturation was achieved after 20 
interviews, two more interviews were conducted to confirm this, and then recruitment 
was halted. 
 Attempts were made by the investigator to contact Governor Pataki and 
Commissioner of Health, Kenneth Pass, as legislative representatives, however, neither 
responded to the invitation to participate. Two of the metabolic specialty center directors 
were not available to participate. The specialty center directors mailed a total of 51 
invitations to parents, of which nine responded. One participant was a parent advocate 
and the remaining 12 participants had various medical backgrounds and were involved in 
the operation of the program. Table 7 displays these participants and includes the total 






Study Participant Description 

















Those in a position to make 
decisions about the program 
Governor of New York 1 0 
Commissioner of Public Health 1 0 




Director of Wadsworth Lab 
 
1 1 
Director of Metabolic Disorders 1 0 




Medical directors and 
neurologists at the Metabolic 









Those served or affected by 
the program 
Representative of Hunter’s Hope 
parent advocacy group 
 
1 1 
Parents of infants screened 
positive for Krabbe disease 
 
154 9 
Totals  177 22 
 
 
 Coding analysis. 
 From the thick, rich descriptions of participant experiences with the Krabbe 
disease program, 65 initial codes were assigned to the text of the interview transcripts. 
These preliminary codes served to describe initial findings in the data, and to discover 
emerging similarities or areas of interest meriting further exploration in future interviews.  




eight categories. These categories reflected relationships and patterns found in the coded 
data.  Once categories were established, further review of the data revealed similarities, 
resulting in elimination of two categories and creation of final themes. Themes represent 
the overarching concept that is found throughout the categories. Morse (2008) describes a 
theme as, “the meaningful essence that runs throughout the data,” ( p.727). 
 Table 8 displays the initial codes, categories, revisions, and final themes, as well 
as the percentage of contribution to each theme by parent and medical participants. For 
example, codes found in the Information Needs category, such as Advice, Parent 
Education, and Clarity of Information reflected the ongoing process of Communication, 
and were merged into that theme. The category Treatment was eliminated, as the codes in 
this category described other phenomena. The code Challenges to Krabbe screening was 
moved from the category Treatment Issues to the theme Unintended Consequences, with 
the rationale that challenges to Krabbe screening were not desired outcomes of the 
program, and were moved to the theme that captured this concept. 
 There were also codes initially assigned to one theme, but after further analysis, 
were found to better represent something else. For example, Treatment Issues and Erring 
on the side of caution were initially coded as examples of the emerging Knowledge and 
Science concerning KD. However, after several interviews, and using constant 
comparison, it became evident that this knowledge presented dilemmas for the medical 
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	 The five final themes that emerged were Legislative/Political, Unintended 
Consequences, Knowledge and Science, Communication, and Moral Issues. Each theme 
is discussed in detail with exemplar quotes provided in the following sections.  
	 Theme: Legislative/Political. 
 In New York State, the Public Health Law §2500-a grants the Commissioner of 
Health the authority to add conditions to the newborn screening panel by regulation 
(Expansion of the New York State newborn screening panel, 2006). This is an example of 
legislation; the action of making or changing laws. The addition of KD was legislative, 
however, the process that brought the issue to the attention of legislators was political. 
The term politics is defined by Mason, et al. (2007), as the process of influencing the 
allocation of resources structure or affairs of the government.  
 Both medical and parent participants spoke about the politics surrounding the 
legislation leading to the addition of KD to the screening panel. Medical participants 
contributed 67% of the content of this theme, while parents contributed 33% of the 
content. The Legislative/Political theme includes comments regarding not only the 
political process involved, but also the concept of being mandated to test. 
 Patient advocacy groups have been influential in the establishment and expansion 
of newborn screening (Clayton, 2010; Paul, 2008). These advocacy groups are comprised 
of parents with affected children and exert voting power, and political contributions. The 
mission of advocacy groups is often singular, as expressed by this medical participant: 




details of the condition.  But again, granted, not a public policy person by any 
means, going to a governor, and I don't think Governor Pataki had any extensive 
background in neurology or genetics and basically, both of them deciding this is 
what needs to be done.  You know, it just seemed like for a lot of the directors 
that that was a little bit strange to be making the decision with such far-reaching 
implications without even having a discussion.  (M02) 
 Considering that decisions regarding inclusion of new conditions to the newborn 
screening panel in New York State must serve the goal of preserving public health 
(Expansion of the New York State newborn screening panel, 2006), a condition must be 
recognized as a threat to the public. If there is little awareness of a condition, as there 
often is in rare diseases, no recognition of threat can exist.  If awareness about a disease 
can be increased, perhaps more research toward treatment or a cure will occur. To this 
end, advocacy groups have used the political process to push inclusion of rare diseases in 
newborn screening, which in turn raises public awareness as infants screen positive. Even 
if no disease is confirmed after a positive newborn screen, families of these infants are 
now aware of the condition, the infants’ pediatricians are now aware, and the disease may 
now be perceived as a threat. One participant describes this as a poor use of the political 
process:  
What goes wrong with the newborn screens?  … the advocacy groups or the 
parents’ groups and so on [recognize] that… there is not treatment and therefore 
we need this program to force the experts to recognize that there is a need for 




 In addition to advocacy groups, pharmaceutical companies and other corporate 
entities that stand to profit financially from identifying diseases early may exert political 
influence. Medical participants expressed concern that the political process of lobbying 
carries more weight than available solid science. This concern is summarized by this 
participant: 
Well, I think you can look at Krabbe and wonder what the driving force was.  You 
know, these [screening tests] are not being physician driven.  I think that they’re 
being driven by consumers and/or biotech firms…and these advocate groups. 
(M08)  
Other participants add that the scientific evidence to support addition of new disorders 
has been superseded by the political process. As one medical participant states: 
…unfortunately, newborn screening has become imbued with politics, as I guess a 
lot of things are.  And it's sort of drifted away from the kind of rigorous scientific 
goals that started it. (M02) 
 Medical participants questioned the ability of parents, legislators, and lobbyists to 
interpret available scientific evidence. There appeared to be incongruity between science 
and the political process. As the decision to add KD to the newborn screening panel 
advanced, the medical community questioned this action, but was not given an 
opportunity to adequately voice their concerns.  One participant describes feeling unsafe, 
and ultimately deprived of the ability to protect patients from the potential consequences 




So I think this was driven politically. It was driven by people who didn’t ask the 
right questions, it was not politically safe, it was not safe to ask the right 
questions…and we as a special team failed to protect these lay people from 
themselves. (M07) 
Another medical participant voiced a similar opinion, regarding the lack of discussion 
surrounding the implementation of the screening test into practice. When adding a new 
condition to the panel, the process of parent notification, reliable confirmatory testing, 
and adequate follow-up procedures for those infants who screen positive must also be 
considered. This participant acknowledges the lab test was available, but points out that 
in the case of KD testing, little input had been sought to figure out how the test would 
work in practice: 
…although they had given good thought to the how do you do it in the lab in 
terms of the routine newborn screening and so on, it didn’t seem to me that any 
thought had been given at all to how we were going to implement this in terms of 
what it meant when you had a positive screen. (M05) 
 The legislative mandate came as a surprise to the metabolic specialists. The 
political process was perceived to carry greater weight than the expert opinion of the 
physicians, who did not feel they were part of the decision making process. The idea that 
a condition was added seemingly without full appreciation of the newborn screening 





 Parents described their understanding of the political process differently. It was 
assumed that because newborn screening was a law, there was a review process in place 
to determine the conditions to include. This assumption allowed parents to accept that 
Krabbe screening was necessary. Although the process was not well understood, this 
parent was certain the rationale to add conditions was valid. 
… it's whatever the state legislature deems appropriate.  They just don't add stuff 
willy-nilly, which I understand… somebody deemed it necessary.  It got on 
somebody's radar somewhere to add this to the list of mandatory newborn 
screening tests.  So I didn't really question the necessity of it.   (P07)  
 Another parent acknowledged the political process and offered his perception of 
what may have influenced the inclusion of KD on the panel, “I mean like somebody's 
friends with some football player; his kid has this and now it's a law,” (P01). While 
disagreeing with the political process, he also acknowledged the importance of newborn 
screening as a public health law. Begrudgingly, he commented about the importance of 
screening to those found to be affected in relation to his family’s discomfort with the 
process: 
 …well that's kind of a dumb law.  But it didn't hurt us as much as it probably 
helps the people that need to know that their kids had it.  So it's really hard to be 
too upset about it.  It's like getting a vaccine.  If your kid is the one kid who reacts 
negatively to a vaccine, it's hard to be like - well we shouldn't get vaccines. 
You're just the lone guy that's out of luck. (P01) 




also understood this testing was important for their infant, there were concerns regarding 
their options. The underlying mandate, the feeling of not having an option to refuse 
confirmatory testing contributed to these concerns. One parent recalls: 
I was just kind of like, my God, we really have no choice about, you know, like 
this was something we were kind of pressed into, and we're handing over 
insurance cards, and you know, thank God we have good insurance.  But, you 
know…I did have a moment where I was like, what am I getting myself into?  
Am I going to end up with some kind of, you know, massive financial 
responsibility?  Which, you know, at that moment it's not the first concern, but it 
was alarming.  (P03) 
 Other participants acknowledged this concern about financial obligation. One director 
comments not about the screening, but about what would happen to families who pursued 
treatment: 
…now what this is going to do is for those kids that can't pay, they have families 
who can't pay? It's going to cost a fortune…either a quarter of a million or three 
hundred thousand for a transplant.  (D03) 
 In summary, the Legislative/Political theme revealed that participants understood 
that newborn screening was a legislative mandate. They stated concern about politics 
having a greater influence in decision-making than expert interpretation of scientific 
evidence. Medical participants expressed their opinion that decisions were made based on 




screening, and described their concerns were not heard. Interestingly, on page 9, 
paragraph 7 of the Emergency Rule legislation, the statement is made that, “There 
appears to be no potential for organized opposition.” However, the metabolic specialists, 
who would be impacted by this decision, expressed surprise about the mandate, and felt 
they were not provided the opportunity to oppose the decision. 
 Parents assumed the legislative process to add new tests to newborn screening 
was sound, and also understood the importance of screening for the population. However, 
the impression of not having an option in the process, and that financial obligations could 
become an issue remained concerns for parents and medical participants alike. 
  	 Theme: Unintended consequences. 
 The concept of unintended consequences refers to the actions of people, 
especially the government, having effects that are unanticipated or unplanned (Norton, 
2008). These effects may be a positive unexpected benefit or a negative effect contrary to 
the original intention of the action. The theme Unintended Consequences includes 
positive effects that were unanticipated by those making the decision to add KD to the 
newborn screening panel, as well as negative issues that have emerged since the 
screening program began. In this theme, parent participants contributed 63% of the 
content and medical participants contributed 37%.  
 One positive benefit of adding KD to the newborn screening panel is the 
increased awareness of the disease by parents, their families and medical professionals. 





So, you know, that's something that I would pay attention to, if there were 
something that came up about Krabbe disease where there were new findings, or 
just something you know, in the media that I had access to, I would pay close 
attention.(P03) 
Another parent described that after learning more about KD, she recognized how the 
disease must affect other families.  After the confirmatory testing revealed no risk to her 
child, her increased awareness led her to search for ways she could help families with 
children diagnosed with KD. This parent recalls:  
 I found a foundation … that does research or something, and I know we initially 
made a donation right after, because we were so grateful that we weren’t 
[affected], but we felt so sympathetic to a family that was going through 
something like this. (P08) 
 However, there were also unexpected negative consequences to adding KD to the 
screening panel. Physicians are aware that notifying parents of a positive newborn screen 
creates an emotional response, but they report being unprepared for the intensity of this 
response from parents where KD was concerned. Perhaps the response was due to the 
uncertainty about what the confirmatory results meant. Unlike the other disorders on the 
panel, with KD, “we were kind of unclear as to how to proceed, which babies would be 
high risk, which babies wouldn't be high risk,” (M01).	These medical participants 
reported their experiences with parent responses ranging from anxiety to denial to anger: 




prefer to avoid us completely. (M01) 
 
So I think we generate potentially this boogieman and I think parents sort that out 
by just sort of walking away from it. (M04) 
  
 …the first high risk family we got just was madder than hell.  We were 
experimenting on a baby, why were we doing this? (M07) 
 Parents’ comments confirmed the concerns of the medical participants. The 
intense emotional response following their notification of the screening results ranged 
from extreme reaction to physical in nature. This parent recalled: 
I had a really hard time that time, I even went to the doctor and they gave me a lot 
of pills for depression and stuff like that…Well, I had trouble.  I started hurting 
myself after that.  It was a way to get the pain off of me, I guess, even though the 
pills weren’t helping. (P05) 
Another parent described her physical reaction stemming from the emotional response 
after being notified of the positive KD screen: 
Yes and my milk went; it dried up and then I re-engorged and she couldn't latch 
on when I re-engorged because - I don't know why - because they were like huge 
rocks.  And so, it didn't end up working out.  I mean I don't know if that [the 
shock of being notified] would do that.  I imagine it would because I was pretty 




	 Another negative unintended consequence was the lingering feeling that their 
child would develop disease later in life. This latent fear may be a result of the risk 
categories defined by the Krabbe Consortium (Duffner et al., 2009) of high, moderate, or 
low risk to develop disease. Being told their child was at low or moderate risk to develop 
KD did not seem to provide sufficient reassurance that their child would not one day 
develop symptoms. Due to this uncertainty, parents reported a lack of confidence with the 
confirmatory test. The following parent comments describe this:  
But to be honest, it was kind of hard to believe, because it seemed like such a 
scary thing in that there were so few false positives, that he was one in such a 
small number.  It was something that I don’t think we really quite trusted [the 
result] until maybe a year later. (P08) 
 
…for the first six months of his life, any time he cried or if he didn't want to eat or 
if something was wrong, you know, not that I expect the worst and hope for the 
best, but I always did wonder in the back of my mind. What if they were wrong? 
(P07) 
 Medical participants’ comments corroborated these parent concerns. Since 
confirmatory test results are delivered with an ambiguous placement into a risk category, 
versus a definitive diagnosis of disease, health care providers couldn’t provide closure for 
some of the families. This lack of definitive diagnosis, the label of “at risk,” fits into the 
concept described by Timmermans (2010) of “patients-in-waiting.” The following 




I think that is a very common feeling I get from the parents, that once you’re 
identified as being at some category of risk, be it low or moderate, you just 
always feel like you have that category of risk. (M06) 
 
I think all of us worry that we’re burdening the family with - sort of labeling the 
kid as defective, and that is not the intent, but it's the end result (M03).  	
	 When KD was added to the panel, the State projected that those infants with early 
infantile onset disease would be transplanted and no further follow up would be required 
by the metabolic center. In practice, the unanticipated finding of infants with very low 
enzyme activity and no symptoms of KD has raised concern among the medical 
participants regarding how long to follow these infants. Boelens (2006), suggests that it 
remains important to follow those at risk to develop KD for the rest of their lives. One 
participant comments: 
…you’re already working with a very anxious parent and then it’s difficult to 
know, now what do we do with these 15 kids, how long are they going to be 
followed, these moderate and low risk kids? (M08) 
	 In summary, the theme Unintended Consequences, participants described positive 
and negative consequences of the KD screening program that were not foreseen in the 
legislative process. Participants described both positive and negative consequences. 
Unintended consequences represent areas that warrant further attention by decision 




 Theme: Knowledge and science. 
 It was understood by all the participants that a legislative process preceded the 
addition of KD to the newborn screening panel and that State law mandated the testing. 
Yet, participants also perceived that there were unanswered questions about KD. The 
process of answering questions and contributing to the knowledge about KD is the basis 
of this theme. 
Knowledge is defined by the Oxford English Dictionary (Soanes & Stevenson, 
2008) as: (1) facts, information, and skills acquired by a person through experience or 
education; the theoretical or practical understanding of a subject, or (2) awareness or 
familiarity gained by experience of a fact or situation. The word science is derived from 
the Latin word scientia, or knowledge (Soanes & Stevenson, 2008). Science refers to the 
systematic acquisition of knowledge through observation and experimentation, with the 
purpose of seeking predictions about future events. Scientific knowledge is disseminated 
through peer review and verification of results strengthens the science. Overall, the theme 
Knowledge and Science includes content about what is known and not known about KD 
and how existing knowledge contributed to the disease being added to the newborn 
screening panel. Science is also included in this theme because this term describes the 
systematic acquisition of new knowledge gained since the screening program has begun, 
through both observation and research. 
The  medical participants and directors provided 94% of the content in this theme,  
while only 6% of the content was provided by parent participants. This discrepancy likely 





Prior to adding KD to the panel, existing knowledge was used to develop the test 
methodology and to make the case for inclusion. What was known about the disease 
shaped the new program and scientific literature provided rationale for the estimated 
number of infants that would be referred annually for confirmatory testing and neurology 
consultations.  One medical participant describes using existing knowledge to create a 
laboratory test that met the needs of a population screening test: 
...it [the only available Krabbe test] was a multiplex mass spec assay for several 
lipid storage diseases, which was done on only a few patients.  …our task was to 
take that and see if we could make it practical and get reasonable results on a 
population on newborns using dried blood samples. … [now]we get it done start 
to finish from the DNA extraction to calling out the results in about 10 hours. 
(D01) 
 Once the Krabbe screening program was operational, the number of referrals was 
found to differ from estimates formulated from the existing literature. In other words, 
science (systematic observation) began to change the existing knowledge about KD. This 
does not apply only to Krabbe screening, but also to other diseases added to the newborn 
screening panel. Participants commented on this concept: 
…whenever you start screening for something new, there are always surprises 
when things don’t go according to the literature…you get an incidence, you get 
what’s available from children who are diagnosed systematically. There are 





…when you start screening, you were going to run into things you never saw 
before. (D03)	
 As a result of the ongoing systematic observation provided by screening, 
emerging science began to replace existing knowledge, particularly when considering the 
prevalence of KD. Before the program began, it was estimated that annually, there would 
be 25 positive screens referred for confirmatory testing, with 2 or 3 diagnosed with 
infantile Krabbe. The later onset forms of the disease were not included in projected 
referrals, since the exceedingly rare incidence of this form of the disease was supported 
in the literature. However, since screening began, there has been an average of 46 
positive newborn screens annually and only 4 infants diagnosed with early infantile KD 
over four years. Surprisingly, there have been 19 infants (5 per year) with low enzyme 
activity, at high or moderate risk to develop a later onset form of the disease. Participants 
discussed this phenomenon as follows:  
Again, before, they said 85% have infantile and 15% have adult onset.  We're 
seeing, it looks as though a lot more have the adult onset.  (M01) 
  
… we were under the assumption when we started this at 80% of kids identified 
with really awful early onset, and they’re not, it’s 20% or something, and 80% are 
[later onset].  So, we learned something. (M03) 
 




thought it was and maybe it doesn’t look like Krabbe disease, or that there are lots 
of people walking around with two mutations. (M07) 
 This new knowledge, that the later onset forms of KD appear to be more common, 
reinforced the medical participants’ assertion that the natural history of this disease was 
largely unknown. The lack of scientific knowledge contributed to the medical 
participants’ objection to the inclusion of KD in the newborn screening panel. They 
expressed concern that without adequate understanding about these later onset forms of 
KD, counseling parents becomes difficult, as answers about age of symptom onset, 
severity of disease, prognosis or treatment cannot be provided with certainty. These 
concerns are described in the following quotes: 
 … we don’t actually know that much about that [high] category of risk… we don’t 
know about late onset disease.  (M06) 
  
…there is such wide variation with the later onset forms, that’s the problem, so that 
you do have a cadre of kids…less than 3 [years of age]so rapidly deteriorating, 
but then you get others who have very minor problems. (M05) 
  
 Usually the families want to know a black and white answer. Is my kid in danger 
or is my kid not in danger? If my kid is not in danger, than why are you telling me 
that my kid is in danger? (M03) 




providing advice to parents, all agreed that the screening test has provided new 
knowledge. A medical participant expressed the addition of KD as, “…a real opportunity 
to expand knowledge of the disorder and the issues within the families and so forth.” 
(M04)  
  Many participants compared Krabbe to the other metabolic disorders on the 
current newborn screening panel where the natural history and biology of the disorder is 
well known. The treatments for the other disorders are either effective, or the limitations 
of treatment are well known. By using comparison to other disorders, medical 
participants were able to describe how incomplete knowledge increased their discomfort 
regarding interaction with families. This discomfort is summarized in these participants’ 
comments: 
With sickle cell disease, it's easy, you have to point out change in the DNA when 
you have sickle cell disease or you don’t.  For this[Krabbe], you know, how do I 
explain to a parent that this one polymorphism knocks the enzyme down by 10%, 
and this one knocks it down 30%?  (M03) 
 
And frankly, if we are a little bit too aggressive with a kid with PKU, we can 
quickly correct it because we see them frequently and we monitor them.  If we're 
a little too aggressive with a baby who might not have Krabbe disease and they 
end up going for transplantation and they end up with complications for the 
transplant, there's a lot more risks to that than there are risks to the others 




 Other medical participants argued that without initiating screening, the new 
information about incidence of later onset KD would not have been known, and 
furthermore, there could never be a gain in knowledge without data gathered as a result of 
screening.  The State mandated the addition of KD to the newborn panel based on best 
available evidence, and as illustrated in the following quotes, screening the newborn 
population for the disease provides information that would otherwise never have been 
known. These participants comment: 
It's almost like a catch-22 argument because you're not going to know until you 
do it, but people think you shouldn't do it until you know, and it's as if we've 
practiced medicine that way.  No medicine is practiced that way. …we'll do it, 
and then they report their data, years down the road somebody does an evidence 
review, and makes an assertion… But, you've got to do that [initiate screening] to 
accumulate any evidence to sway one way or another, because there is no 
evidence in the beginning.  (D01) 
… [Krabbe screening is] analogous to doing sort of a broad population-based 
research program project.  Because the act of doing the newborn screening was 
itself going to answer questions that we didn't know about the condition.  And that 
we actually couldn't answer very well until you did start the newborn screening. 
(M02) 
  Medical participants were concerned about the impact of the test results on 




knowledge. However, parents seemed to understand that KD was a new addition to the 
screening panel. Their comments indicate that because of this novelty, the physicians 
may not know everything about the disease. Two parents commented on the novelty of 
the test:  
I guess I understood [that this test was new] based on the fact that this is not a 
disease that’s terribly well understood. (P02) 
 
…they only had two examples to show as far as success rate [of the test] was 
concerned, because up to that point, they didn’t really know what they were 
dealing with, I guess, was the impression I got. (P06) 
 Parents described their new knowledge about KD differently than the medical 
participants. Instead of being concerned about what was not known about the disease, all 
parent participants expressed the idea that knowing their child carried a gene KD was 
important. One parent described this gain in knowledge in the context of considering 
what may have occurred if her baby had KD: 
… to know one way or the other was really important to us, and when I found out 
what it [Krabbe disease] was and how quickly it hit, that knowing part would be 
so vital because the amount of time that you would have is so short, and whatever 
plans you have to make in terms of care and how to deal with the disease would 
have to be made so quickly. (P08) 
 Another parent offered her opinion regarding screening for KD, and the belief that 




I think that’s a good idea that they do screen for Krabbe because I would never 
believe my child could have Krabbe, it’s beyond thinkable.  I would think…they 
should screen for any of that kind of disease in every state, not only New York 
State, all throughout the states. (P05) 
In summary, medical participants discussed KD as something they knew little 
about and that by implementing screening, emerging knowledge is contributing to the 
scientific knowledge. Medical participants differ in their opinions about whether the 
addition of this disease to the newborn screening panel was premature, citing the lack of 
knowledge about natural history, variability of symptom onset and severity, and the 
resulting inability to provide a concrete prognosis. Others argue that without initiating 
screening, new knowledge, such as the surprising finding that later onset forms of KD 
may be more common than the literature had supported, or that low enzyme activity may 
not result in symptoms would never be known. However, this new knowledge reinforces 
the premise that insufficient scientific knowledge demands further research about the 
disease. Medical participants express being comfortable with the other disorders on the 
panel because the biology of the disorder and limitations of treatment are well known.  
When parents described their knowledge about KD being part of the newborn 
screen, there seemed to be an understanding that this was a new addition to the panel and 
that it was important to know whether their new baby had this disease.  Parents were 
generally supportive of KD screening, and satisfied they knew important information 
about their child’s health. In this way, the KD screening program appears to be meeting 




York State Department of Health, 2006b, para 1). 
 Theme: Communication. 
 Information about KD is transferred using the complex process of 
communication. A simple description of this process is that information is sent and 
received. The transfer of information may include actions that confer knowledge and 
experiences, give advice and commands, ask questions, or seek information. All of these 
actions are a part of the newborn screening process. Furthermore, communication may be 
effective or ineffective. In effective communication, the intended recipient understands 
the information being sent as the sender intended the message to be understood. 
Ineffective communication implies the recipient does not understand the intended 
message. While knowledge about KD can contribute to the message, communication 
focuses on how that message is being sent. 
The theme of Communication includes the activities surrounding the transfer of 
information about KD from person to person with the intent of sending a message. This 
transfer may be effective or ineffective, and may include not only face-to-face 
communication, but also the transfer of information from other sources, including the 
internet. 
 All the study participants discussed various communication activities, however, 
differences between medical personnel and parents were observed. All of the parents 
spoke at length about the communication process; how they were notified about the test 
results, what information medical professionals provided, where they found information, 




parents, this theme was multifactorial. For physicians, their comments centered on 
concerns they had about trying to provide useful information to parents, and contributed 
37% of the content to this theme. 
 The entire process of newborn screening begins with parents understanding their 
infant is receiving screening, as well as what the infant is being screened for. To address 
this, some states require parental informed consent prior to collecting blood (US General 
Accounting Office, 2003, pp 22-23.). New York State does not require consent for 
newborn screening but hospitals or birth attendants are required to provide education 
about the screening test (Test for phenylketonuria and other diseases and conditions, 
1997). This education is often provided using a pamphlet describing screening without 
any verbal notification prior to the test. Many parents commented that they were unaware 
their infant had been screened in the hospital. These parents commented:  
… because we honestly didn’t even know that this was something that happened; 
that there was any blood taken from the baby at the hospital, or that the state runs 
specific tests for specific things. (P08) 
 
I don't think he was screened when I was in the hospital.  I think it was out [of the 
hospital].  (P04) 
 
…they didn’t even tell me that they were screening for it. (P05) 
Since they were unaware that a screening test had been performed, the initial 




experiences about the communication of their baby’s screening result, several cited the 
opportunity to talk about this as their reason for participating in this study. The initial 
notification was often experienced as a traumatic event that came as a surprise. The way 
parents experienced the communication of a positive KD screen is described poignantly 
in the following comments: 
Her old pediatrician, one of the doctors there, called at five o'clock on a Friday 
afternoon and told me that there's something seriously wrong with my daughter. 
(P02) 
 
…one of the scarier parts for me  was getting a call from some hospital that I had 
no affiliation with and telling me that they had test results from my son and that I 
needed to come in immediately.  (P08) 
 
That was the worst part of this whole thing, was how I was notified…so the whole 
process was nerve-wracking only because of the way I was notified.  It was like a 
baseball bat out of nowhere. (P07) 
 
…it devastated me.  I was in shock.  All I remember is he said that he had Krabbe 
disease and it’s pretty serious, he can die within a year and they need to get tested 
and stuff like that. (P05)	
 





 After this initial notification, some parent participants sought information from 
their pediatricians, only to learn that the pediatricians either had little information or none 
at all.  This lack of information caused more anxiety for parents as expressed in the 
following comments: 
And the doctor said, ‘Unfortunately I've never heard of this before; it's the very 
last item that's on the list of screening tests that they do,’ and, ‘It's terrible that I 
don't have more information for you, but it is what it is …’ So, of course, you 
know my son is ten days old and you hear something that comes back off 
newborn screening, you immediately think the worst.  And then with the doctor 
not having any information for me, other than somebody called them and let them 
know. (P07) 
 
Our pediatrician got the report, like the CDC information, and he acknowledged it 
on our next visit, but he didn't, you know, have any specific information, and 
honestly, I think he didn't have any information.  I think he … was not terribly 
familiar with Krabbe disease and was relying on sort of the information that was 
given to him… (P03)	
 
And the pediatrician in the local doctor's office had no information whatsoever to 
share with me at that time. (P06) 




their infant had been screened while in the hospital. When they received notification of a 
positive KD screen, they described shock and needed reassurance and information. 
Unfortunately, parents reported their pediatricians were unable to provide this. Without 
information available from their pediatricians, parents were left to seek information 
independently and did so from a readily available resource, the internet. Parents report 
their experiences searching for information about KD on the internet: 
 I mean I got more off the internet than what the doctors could tell me. (P02) 
 
But beyond that, if you just Google Krabbe disease, you get more information that 
you don't want because it's all the terrible stuff.  (P07) 
 
… like WebMD.  And what do I remember about it, just that it's a neurological 
disorder that is really bad news. (P01)  
 Medical participants were sensitive to the anxiety that parents could experience 
when notified of a positive screen and were aware that this was not always handled well. 
They acknowledged the way the initial positive result was communicated made a 
difference in the ongoing process of confirmatory testing and follow up. One participant 
commented: 
I think that that's a very important point that the director or physician involved 
with that initial encounter plays a big role in that of course.  …  So the 





 In addition to the communication of initial screening results, ongoing 
communication with parents was described as difficult because there was inadequate 
information about KD available to the medical participants. The lack of information 
about later onset forms of the disease, in addition to the known variability of onset and 
severity of symptoms left medical participants with little evidence to rely upon when 
counseling parents. Their ability to recommend follow up and provide reassurance was 
compromised due to this paucity of information. Providing advice to parents became 
problematic as discussed by the following medical participants:  
So, you know that information is hard to give to a brand new family with a brand 
new baby, "You might have a horrible disease and we have a treatment that might 
end up with the child dying anyway," And it's a big decision to make [seeking 
treatment], but we don't have all that information [about effectiveness] yet.  And I 
think that that's also very important to have when you're counseling a newborn 
family.  (M01) 
 
I think that part of what’s tricky is that even when their confirmatory enzyme 
testing comes back as normal… we really think that they’re unlikely to develop 
disease, that they’re more likely to be carriers…I just think that those patients, 
because they are identified for follow-up…get a lot of confusing information 
about what their diagnosis is. (M06) 
Parents also expressed that once informed about the screening result; there was 




information about the disorder, what the confirmatory test results meant, or about 
prognosis of KD. Compounding this lack of information about KD was the feeling that 
even the specialty centers were not able to provide them with sufficient answers to allay 
their fears. As a result, some parents described the feeling of being misled, as exemplified 
in this parent’s comment: 
I came in this like blank, I didn’t know anything, and they wouldn’t even tell me 
anything.  They could just tell me like there’s nothing to worry about. [But] They 
didn’t tell me that, they said it could be a big issue. (P05) 
Another parent described increased anxiety after her child’s metabolic consultation: 
So, I think the fact that I was just sort of…there was just this sort of lack of 
information… that it created more anxiety for me. (P03)  
  
Other parents remained confused about their child’s status resulting from incomplete or 
ambiguous information provided to them: 
Ok, well, do we truly have nothing to worry about if [my baby] is just a carrier?  
What does "just a carrier" mean? (P07) 
 
…he [the medical provider] gave me the rundown of what it is and then told me 
that he's not in the danger zone.  He's not in the good zone.  He's right in between, 
so he might not have anything happen to him. (P04) 
The lack of trust, increased anxiety and continuing confusion described by parents 




information about KD.  Medical participants were aware that their communication with 
parents was deficient. This is exemplified in the following comments: 
I think parents recognize that there’s something that’s not being said, that there’s 
something that doesn’t make sense and that’s not really clear. (M06) 
 
[Physicians] are the ones who are running into issues with what do you tell, what 
does moderate or low risk mean?  And as a parent, I would probably be concerned 
about that.  (D02) 
 In conclusion, all participants acknowledged that communication is a difficult part 
of the KD screening program. Although educating parents about the newborn screen 
process is included in the public health law, most of the parents interviewed were 
unaware their infant had been screened in the nursery. Parents described distress over 
how they were notified of the results of their infant’s newborn screen and medical 
participants acknowledged both the importance of this initial notification and the 
awareness this was not always presented well. Furthermore, meaningful, dependable 
information was found to be unavailable to both parents and medical participants, 
resulting in communication that engendered mistrust and misunderstanding. 	
	 Theme: Moral issues. 
 Morality is based on acceptance of certain accepted principles. In medicine, these 
principles are the values of Autonomy, Beneficence, Non-malfeasance, Justice, Dignity 
and Honesty. Autonomy describes a patient’s right to choose or refuse treatment. 




malfeasance is often expressed as “first do no harm,” meaning the treatment should not 
harm the patient, or if it does, will provide a greater benefit than harm. Justice is based on 
the concept that treatments and access should be equally available to all. Dignity refers to 
the right of all persons to be treated with respect. Honesty is the provision of all the facts 
without censor (Beauchamp & Childress, 2001). The criteria for population health 
screening written by Wilson and Junger (1968) were based on these principles of medical 
practice. The theme of Moral Issues consists of comments representing conflicts of these 
moral principles described by participants surrounding the KD screening program. 
Medical participants contributed 100% of the content to this theme, perhaps reflecting 
that parents were unaware of any issues surrounding KD testing. 
 With the addition of KD to the newborn screening panel, a new precedent had 
emerged. Newborn screening could now include diseases that did not adhere to the 
Wilson and Junger (1968) criteria for screening. The opinion was that any disease could 
be added to the newborn screening panel if there was sufficient support, regardless of 
meeting the criteria for inclusion. One medical participant stated: 
So again, it's just opened a Pandora's Box on many levels.  It sort of gone against 
a lot of tenets of what newborn screening was sort of initially intended to do.  
That it sort of opened up a whole range of other competing interests to sort of get 
their foot in the door and say, "Why not do that disease then?" (M02) 
 Medical participants assert that the addition of KD to the newborn screening panel 
was premature because there was insufficient scientific knowledge about the disease.   




toward the understanding of a disease. Some of the medical participants contend that 
screening for KD is actually research, but because it is mandated by the State, families 
are not given the option to decline participation.  The idea that research is being 
conducted on a vulnerable population without the opportunity for informed consent 
violates the principle of autonomy. This caused concern for some of the medical 
participants, as illustrated by these quotes: 
… a lot of our treatment remains in this experimental research realm and that 
patients need to be protected by research protocols and consents. (M06) 
 
So if the state didn’t want to consent the patients early on then they at least 
needed to take responsibility for the fact that this was an experimental venture and 
that they are creating a population of children who can only be understood as 
research subjects. (M05)	
 Other medical participants argue that while screening for Krabbe may provide 
data that could be used for research, the screening is mandatory, and all newborns born in 
the state are receiving the same test.  Because the test is mandated, everyone must 
comply with the law, including the physicians. There is no discrimination; everyone is 
participating equally, thus meeting the principle of justice. These participants describe 
their opinions about mandated research:  
So while I may have philosophical disagreements with how it was all started, at 
this point, it's something that is done on every baby.  And if a parent comes in and 




like the horse is out of the barn already because we've already gotten the test 
back. (M02) 
 
…when they say it’s,” Oh, you’re doing research”.  And, yes, I think a lot of this 
is research, but this is mandated. … if this wasn’t mandated we wouldn’t be doing 
this.  But since it is mandated and we’re doing it, you kind of have to do the 
research. (M09) 
 The finding that infants are identified with very low enzyme activity but without 
the early infantile onset symptoms caused some of the medical participants to question if 
the State is adhering to the established guidelines for newborn screening. The very low 
enzyme activity may develop into a later onset form of KD; however, there is no 
predictive test that can provide that information, or it may never cause symptoms. Even if 
physicians were able give families a prognosis, only early infantile KD has a proven 
treatment (Escolar, Poe, Martin, & Kurtzberg, 2006; Friedman, 2008). By identifying a 
disorder that may not display symptoms until much later in the child’s life, there is now a 
precedent for identification of adult onset diseases being added to the newborn screening 
panel. This precedent challenges the principles of honesty and non-malfeasance. These 
medical participants described their concerns in the following comments: 
There are two things that I think make this current process unethical.  One is that 
we can’t tell affected from unaffected, and the other is that we’ve done this 
[began screening for Krabbe disease] knowing we couldn’t without getting 





So, in fact, have morphed…from a newborn screening program into a program 
that is screening infants for potentially adult onset, very variable diseases that are 
really hard to explain. (M01) 
 Another issue discussed by the medical participants was that the treatment for 
early infantile onset KD, UCBT, is associated with high morbidity and mortality 
(Friedman, 2008). The treatment may also be less effective than suggested in the original 
published research (Duffner, 2010; Friedman, 2008). The knowledge that the treatment is 
not as effective, and may cause further illness or death violates the principles of 
beneficence and non-malfeasance, creating a dilemma among the medical participants. 
Many expressed concern that they are not offering families a cure, but rather a treatment 
of questionable efficacy. The medical participants commented: 
What a huge commitment and a huge decision to decide to do a transplant on 
somebody and then it’s not like you’re going to do that and make them 
completely normal. (M08) 
 
…you know, it[transplant] attenuates the disease, but it does not cure it, and that 
most…I don’t know that all, but most of these children over time do seem to have 
a slow deterioration.  (M05)  
 
…the reason for the treatment was to be compassionate, yet nobody thinks about 




significantly impaired and only to get worse. (M07) 
 
You know in Krabbe disease, so even if they survive the transplant, there are 
issues.  We know that now, that they still have motor difficulties. (M02) 
 
…we can promise them that their enzyme deficiency might be eliminated but we 
can’t promise them a normal neurologic outcome. (M06) 
 In conclusion, medical participants were vocal about their moral conflicts 
surrounding KD screening. Some of the medical participants raised concerns about the 
moral challenges of screening for a disease that may not display symptoms until later in 
life, which challenges the principles of honesty and beneficence. Other medical 
participants described concern about conducting a form of research without full consent 
of everyone involved, violating the principle of autonomy. The legislative goal of adding 
KD to the newborn screening panel is to identify infants with serious but treatable 
medical conditions (Expansion of the New York State newborn screening panel, 2006). 
Medical participants were concerned that the treatment of KD, a UCBT, may not be as 
effective as initially reported, challenging the principle of beneficence and non-
malfeasance.  
 Summary. 
From the emergent content analysis of stakeholder interviews and investigator 
field notes, five themes were identified: Legislative/Political, Unintended Consequences, 




provided evidence to support that screening for KD at least partially meets the goals set 
by New York State.  
All the stakeholder groups understood that KD screening was a legislative 
mandate. Parent participants concluded that legislators had sound reason to add KD to the 
panel, while medical participants expressed their opinions that emotional pleas from 
parent advocacy group agendas and financial support from lobbyists superseded scientific 
evidence. 
Medical participants discussed the emotional reaction to the news of a positive 
KD screen was more intense than the other disorders on the newborn screening panel. 
Parent participant comments supported this assertion, revealing concerns about maternal 
health as an unintended consequence of screening for KD. Medical participants also 
worried that by placing an infant in a risk category, parents may be concerned about their 
child developing KD in the future. Parent participants did describe a latent fear of 
disease, but also described an increased awareness of KD and did not view this 
unintended consequence negatively. 
 Parent participants recalled their experiences surrounding communication of 
positive KD screening result. Although education about screening is required as part of 
the public health law, only one parent was aware that screening had been conducted in 
the nursery. Parents vividly recalled feelings of fear, stress, and in some cases, reacted 
with physical illness. In addition, parents reported that the information received from 
both their pediatricians and the metabolic specialty centers was insufficient, ambiguous, 




 Medical participants discussed the finding that newborn screening for KD was 
identifying infants with low enzyme activity and mutations found in persons with later 
onset forms of KD. They expressed concern about the lack of knowledge about the 
natural history of these later onset forms and discussed how this impacted their ability to 
effectively communicate risk to parents. They also discussed perception of moral 
dilemma regarding the treatment of KD and the concept of conducting research without 
parental consent. 
 Overall, parent participants expressed support for newborn screening, understood 
that it was mandated, and seemed to understand that KD was a new disease added to the 
screening panel. Parents were grateful they had information about their infant’s health; 
however, it was unclear whether they understood what, if any significance the 
confirmatory results had for their infant. Medical participants perceived KD screening as 
premature, citing a lack of knowledge about the later onset forms of the disease that were 
being detected through newborn screening and concern about the risk and effectiveness 
of the UCBT for early infantile KD. 
Aim 2  
Assess the Krabbe disease test characteristics with the most recent data available. 
New York State has published annual reports detailing all newborn screening 
results since 1990.  These reports are available to the public on the Wadsworth Center 
website (Wadsworth Laboratory, 2009). Krabbe disease screening results have been 
included in the annual report since the program began in August of 2006. Confirmed 




confirmatory enzyme testing at the Lysosomal Diseases Testing Laboratory in 
Philadelphia, Pennsylvania. This risk category includes all infants with 
galactocerebrocidase enzyme activity less than or equal to 0.15 nmol/h/mg protein 
(Duffner et al., 2009).  Infants with enzyme activity 0.16 to 0.29 nmol/hr/mg protein are 
placed in a category of moderate risk to develop KD. Both the high risk and moderate 
risk infants are recommended to receive the same neurodiagnostic work up (MRI, LP, 
BAER, and NCV) and neurologic consultation. But infants in the moderate risk group are 
not reported as positive on the State annual reports. 
 As of July 2010, there were 1,062,000 infants screened. 187 infants were referred 
to a metabolic specialty center for positive Krabbe screening and to receive confirmatory 
enzyme testing. Two families declined to bring their child for confirmatory enzyme 
testing, and 185 infants were evaluated at one of the metabolic specialty centers. Of the 
28 infants with positive confirmatory enzyme testing, 19 infants were categorized at 
moderate risk to develop KD, five infants were placed in the high risk category to 
develop KD, and 4 infants were diagnosed with early infantile KD. Figure 3 displays the 
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Enzyme Activity ≤0.15 
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 Data from the public annual reports (New York State Department of Health, 
2006c, 2007, 2008, 2009) were used to populate the contingency table in order to 
calculate sensitivity, specificity, positive and negative predictive values, and prevalence 
of KD in New York State since August of 2006. (Table 9) 
Table 9: 
Contingency Table - State annual report 
 
Newborn Screen 
test result Krabbe Confirmatory Testing 
 









        (a) 
         9 
False Positive 
         (b) 







        (c) 
         0 
True Negative 
         (d) 




Totals          9     1,061,991 1,062,000 
 
Note:  
Sensitivity = a / (a + c) = 9/ 9+0 = 1.00 X 100 = 100% 
 
Specificity = d / (d + b) = 1,061,815/ (1,061,815+176) = 0.99 x 100 = 99% 
 
Positive Predictive value = a / (a + b) = 9 / (9 + 176) = 0.05 x 100 = 5% 
 
Neg. Predictive value = d / (c +d) = 1,061,815/ (0 + 1,061,815)=1.0 x 100= 100% 
 
Prevalence = 9/1,062,000 x 100,000 = 0.85/100,000 
 
 
 All nine infants categorized as true positive for KD had enzyme activity ≤ 0.15 
nmol/hr/mg protein and mutations of the GALC gene. Four were diagnosed with early 
infantile KD, and had the 30KB deletion associated with this form. Of these infants, three 
had undergone UCBT. One infant died during the transplant process, the other two 




third percentile for height and weight. One family opted not to pursue transplant and the 
infant deteriorated as expected. The remaining five infants in the true positive group are 
asymptomatic (Duffner, 2010). 
 However, it is important to note that the annual reports omit those infants who fall 
into the moderate risk group (GALC level 0.16 ≤ 0.3 nmol/hr/mg protein). Most of these 
infants have one or more mutations and several polymorphisms that are known to 
decrease enzyme activity. The Krabbe Disease Consortium has recommended neurologic 
evaluation every 3 months for the first and second years of life, including the battery of 
neurodiagnostic studies (Duffner, Caviness et al., 2009). As of July 2010, 19 infants fell 
into this category, but were excluded in the annual report. These data were obtained 
through the meeting minutes of the KD Consortium (Duffner, 2010). Table 10 presents 
these data to calculate test characteristics to include all children with low enzyme 
activity. 
Table 10: 
Contingency Table-including moderate risk infants 
Newborn Screen 
test result Krabbe Confirmatory Testing 




        (a) 
        28 
 
False Positive 
         (b) 







        (c) 
         0 
True Negative 
        (d) 










Note: Sensitivity = a / (a + c) = 28/ (28+0) = 1.0 x 100 = 100% 
 
Specificity = d / (d + b) = 1,061,815/ (157 + 1,061,815) = 0.99 x 100 = 99% 
 
Positive Predictive value = a / (a + b) = 28 / (28 + 157) = 0.15 x 100 = 15% 
 
Negative Predictive value = d / (c +d) = 1,061,815/ (0 + 1,061,815) = 1.0 x 100 = 100% 
 
Prevalence = 28 / 1,062,000 X 100,000 = 2.6 / 100,000 births 
 
 
 While inclusion of the infants at moderate risk for developing KD does not affect 
the sensitivity, specificity of the test, or negative predictive value, the positive predictive 
value rises from 5% to 15%. The KD prevalence rises from approximately 1/100,000 
births to approximately 3/100,000 births. However, because KD is very rare, the positive 
predictive value will remain low. These results are typical of many disorders on the 
newborn screening panel. In the case of a disease like KD, negative predictive value, or 
the likelihood that a negative test indicates the infant will not develop disease is very 
important. 
 In the emergency rule legislation, the estimate was that 50 to 100 infants would be 
referred annually to metabolic specialty centers, with 95% of those infants ultimately not 
being diagnosed with KD (Expansion of the New York State newborn screening panel, 
2006). For the period of August 2006 through July 2010, the total number of infants who 
had confirmatory testing was 185, or an average of 45 referrals annually. Using the 
estimate that 95% would not have KD, there should be two infants diagnosed in New 
York State annually. In practice, there have been only four infants diagnosed with early 
infantile KD since the screening program began (one per year). However, there have been 




mutations that may indicate one of the later forms of KD.  Inclusion of these infants 
would increase the number of infants with KD to two per year. 
 In addition, there have been 19 infants identified with enzyme activity <0.3 
nmol/hr/mg protein and mutations that may cause a later form of KD. These infants are 
not reported as having KD in the annual report; however, their parents are told that their 
infant is at moderate risk to develop KD. These infants are scheduled for neurology 
consultation and neurodiagnostic testing, and the possibility that they may develop KD 
cannot be excluded. If these infants are included in the group of those diagnosed with 
KD, then there have been seven infants identified annually as a result of this program. If 
the possibility of later onset forms of KD cannot be excluded, then these infants should 
be reported as positive in the State Annual Report to accurately reflect actual practice. 
Aim 3  
Assess the actual costs of the Krabbe disease screening program.  
 Using data from Aim 2, 185 infants were referred to metabolic specialty centers 
for a positive KD newborn screen. These 185 infants all received confirmatory enzyme 
testing. Both parents had DNA analysis of the GALC gene and the infant’s analysis was 
repeated. Table 11 represents the costs to Wadsworth Center associated with a positive 










Wadsworth Center Costs for Newborn Screen Positive Krabbe  
 
Service Cost 
Repeat Screen and DNA analysis 
(infant and parents) 
 
$900 






In addition, the cost of adding KD to the newborn screening panel was estimated at $2.50 
per infant screened (M. Caggana, personal communication, December 4, 2009). If this 
cost is applied to the 1,062,000 infants screened, the total is $2,655,000. 
Table 12 represents costs associated with the metabolic specialty center visit.  
These costs are billed to the families, and are generally covered by insurance. For those 
families without insurance, Metabolic Centers may write off the cost associated with the 
initial confirmatory testing visit. The costs in Table 12 apply to the 185 infants who had 
positive newborn screens for KD. 
Table 12: 





















$26 $10 No data 
 
$24 0 
Totals $726 $283 $844 $97 $72 
 
Note: 
Mount Sinai Medical Center costs-converted from charges using cost-to charge ratio 





United Health Reimbursement 
 
The cost estimated for an infant with a positive newborn screen for KD ranges 
from $72 to $844, with an average cost of $324 (SD = $359). The Wadsworth Center cost 
was added, for a total average cost of $1475 per infant with a positive Krabbe screen. 
When these costs are applied to the 185 infants referred to specialty metabolic centers, 
the total average cost for four years is $272,875.  
 The 28 children with positive confirmatory screens, those with GALC enzyme 
levels <0.3 nmol/hr/mg protein, incurred additional costs displayed in Table 13. These 
costs are billed to parents and are covered by most insurance companies and Medicaid 
(New York State Department of Health, 2006a). 
Table 13: 
















$600 $234 $106 $73 $113 











$213 $62 $317 $74 0 





$759 $296 No data 
 
$101 $50 




MRI with and 
without contrast 
$2500 $975 $2103 $597 $475 
 
Hospital 
























Mount Sinai Medical Center costs – converted from charges using cost-to-charge ratio 
Strong Medical Center costs 
Medicaid Reimbursement 
United Health Reimbursement 
 
On average, it was estimated to cost $2669 (SD = $1224) per infant with a positive 
confirmatory result. Based on the source of the cost data, the range is $921 to $3621. For 
the 28 children with positive confirmatory enzyme results, the total estimated cost is 
$74,732. 
 Over the time period from August 2006 through July 2010, the total cost of the 
program was estimated to cost an average of $3,002,607. This translates into an annual 
average cost of $750,652. For the fiscal year 2006-2007, New York State appropriated 
$11 million to the total newborn screening program, an increase of $2,000,000 from the 
previous year (Governor Pataki introduces 2006-07 executive budget, 2006). In addition, 
Title V block grant funding for 9 population-based services, including newborn screening 
totaled $113,204,948 (McTague, B., 2009). The initial $1150 is paid by the State to 
Wadsworth Center and is not billed to insurance. If the family has insurance, the cost of 




insurance, or inadequate insurance, the metabolic center may absorb this cost (M. 
Wasserstein, personal communication, December 4, 2009). The metabolic centers receive 
no financial support from New York State (ASTHO, 2005), and the decision to absorb 
cost is up to the individual center. However, for those with positive confirmatory test 
results, the costs are not absorbed by the metabolic specialty center. This is not an issue 
for those families with Medicaid or insurance coverage, unless the policy has a high 
deductible or copay. As revealed in the qualitative interviews, cost was a concern for both 



















Chapter V: Discussion 
 In 2006, New York became the first state to add KD to the newborn screening 
panel.  This study is the first formal systematic evaluation of the addition of KD to the 
New York State newborn screening panel and provides a comprehensive evaluation, 
including cost analysis, the input of stakeholder groups involved in the program, and 
assessment of test characteristics using the most recent data available.  Specifically, using 
the CDC Framework for Program Evaluation in Public Health (Centers for Disease 
Control and Prevention, 1999), qualitative and quantitative methods were used to address 
the three aims. For Aim 1, the investigator interviewed 12 medical participants involved 
in making decisions about the program, and 10 parents who were directly affected by KD 
screening. Aim 2 involved gathering test result data from August 2006 through July 2010 
to calculate sensitivity, specificity, positive and negative predictive value, and prevalence 
of KD. In Aim 3, cost and charge data were analyzed to determine cost of KD screening 
from the initial screening in the nursery to the time point of confirmatory neurodiagnostic 
testing from the perspective of the state. In this chapter, the findings from this study are 
discussed. This is followed by a discussion of the implications of the findings including 
recommendations for practice and policy and recommendations for future research.  The 
strengths and limitations of this study are then discussed. Finally a dissemination plan 
provides details of how findings will be presented to inform decision-making for 







Discussion of Findings  
Aim 1. 
Stakeholder interviews provided meaningful input regarding the KD screening 
program in operation. Using content analysis, five themes emerged from these 
interviews: Legislative/Political, Unintended Consequences, Knowledge and Science, 
Communication, and Moral Issues. Themes represent the common meaning found in all 
data included in that theme; however, the themes are interrelated. For example, 
information about KD is in the theme Knowledge & Science, however, when that 
information is given to another person, it becomes Communication. 
Within the Legislative/Political theme, qualitative analysis of interview 
transcripts provided evidence that all parent participants in this study supported KD 
screening, and several indicated satisfaction in having more information about their child. 
Overall, parents believed screening was very important, and although they may have been 
stressed during the process, were grateful the program was in place and endorsed 
screening for as many diseases as possible. This finding is supported in the literature. In a 
cross-sectional study of 1322 prospective parents in the Netherlands, 73% of respondents 
supported newborn screening even for disorders that have no treatment (Plass, van El, 
Pieters, & Cornel, 2010).  Avoidance of a long diagnostic quest is cited as the primary 
rationale for this endorsement.  
Parents expressed belief that there was a rational process in place for considering 
the addition of new disorders to the newborn screening panel. However, this belief was 
not supported by the medical participants in this study, who voiced concern that advocacy 




Patient advocacy groups are not new to the political process involved in newborn 
screening. In a historical review, Paul (2008) described the influence of these groups 
from the inception of newborn screening, with advocacy groups cited as instrumental in 
the adoption of PKU screening. Indeed, patient advocacy groups increased the awareness 
of disparities in state screening panels leading to the formation of a federal advisory 
committee to recommend a uniform panel of tests. When the ACMG solicited input for 
their initial survey to determine which diseases belonged on this panel, private 
individuals and advocacy groups represented 60% of the responses (Paul, 2008). This 
finding lends support to the concerns of the medical participants. These participants 
assert that the legislation mandating KD screening was premature, that scientific evidence 
was insufficient, and advocacy group support superseded this evidence. Indeed, other 
experts have recommended against adding KD to the panel of newborn screening tests 
including the Secretary’s Advisory Committee for Heritable Diseases in Infants and 
Children (Knapp, Kemper, & Perrin, 2009) based on review of existing evidence. 
The theme Unintended Consequences included the unanticipated effects of the 
legislation adding KD to the newborn screening panel. Both positive and negative effects 
were found during qualitative analysis of the interview transcripts. One unintended 
consequence of KD screening for parents was an increased awareness of the disease. 
While increased awareness of a disease is not the intent of legislation, patient advocacy 
groups understand that by screening the population, awareness will increase as a result 
(Paul, 2008).  
Medical participants discussed a heightened emotional response from parents 




as more intense than the usual response to positive newborn screen results. One parent 
discussed using pills, alcohol and cutting herself to deal with the pain of believing her 
infant was going to die, while another recalled that she was so ill physically that her milk 
dried up and she was unable to breast feed. These accounts reflect the medical 
participants’ concerns.  While there is evidence in the literature that parents are 
frightened about the possibility of their child having a disease (Farrell and Kuruvilla, 
2008; Waisbren, et al., 2003), a thorough explanation of the disorder and treatment 
expectations can help reassure them. Perhaps the heightened response to KD screening 
results is explained by receiving incomplete or incorrect information about Krabbe 
disease or perhaps the uncertainty surrounding the confirmatory results contributed to 
parental recollection of the initial notification. 
Another unintended consequence of KD screening was the latent fear that disease 
symptoms would appear. Waisbren, et al (2003) and Gurian, et al. (2006) found that 
parents continue to believe their child is affected even when the newborn screen has been 
confirmed as a false positive. However, after a positive KD screen, the confirmatory test 
results do not always provide the same certainty as other diseases on the newborn 
screening panel. Parents may be told their infant is at high or moderate risk to develop 
KD, or that their infant is a carrier of a disease causing gene. At the same time, 
physicians provide reassurance that their baby is neurologically normal, but to watch 
closely for anything strange. This diagnostic uncertainty creates what Timmermans and 
Buchchbinder (2010) refer to as “patients in waiting.”  They found that parents were 
likely to focus on the potential of disease rather than the reassuring message that their 




watching closely for symptoms for the first year, admitting that even yawning, or 
blinking too often caused them concern.  All of the parents interviewed commented about 
latent fear. Some parents were concerned that the confirmatory testing was not reliable; 
others were confused about the meaning of the risk categories; and all professed worry 
that their child could still develop KD at some point during the first year of life.  
Medical participants provided the majority of the content found in the theme of 
Knowledge and Science. They discussed what was not known about KD, how screening 
has changed the knowledge about the disease, and compared KD to other disorders on the 
newborn screening panel. Since KD has been added to the New York newborn screening 
panel, there have been discoveries challenging what is known about the disease. These 
discoveries have not made diagnosing KD easier, but rather have increased the ambiguity 
surrounding low GALC activity and presence of disease. This ambiguity led to the 
conclusion published in a recent evidence review that “any screening for Krabbe disease 
be conducted in the framework of a research project,” (Kemper et al., 2010) p.543. Since 
infants are being identified with very low enzyme activity and mutations suggesting later 
onset disease (or novel mutations of unknown significance), providers are placed in a 
situation where counseling families about onset and severity of symptoms, as well as 
prognosis and treatment becomes difficult, because little is known about these forms of 
KD.  
Medical participants asserted that the inability of the testing process to predict 
those affected or unaffected by disease should disqualify KD as part of the newborn 
screen. This lack of a predictive test has been documented by the researchers who 




for those clinicians providing counseling to parents (Escolar, et al., 2009). This inability 
to provide counseling regarding symptom onset and prognosis left parents with more 
confusion and distrust described in the theme Communication. They knew their child has 
been diagnosed with something genetic, perhaps a disease that may progress to death, but 
are provided with no information, even from the specialists about what to expect. 
Krabbe disease is not the only newborn screening test that has been controversial. 
Forty years ago, universal screening for PKU was controversial as well. Disagreement in 
treatment methods and unknown variation in the presentation and natural history of PKU 
led to infants being “over treated” with a protein - restricted diet (Brosco, Sanders, 
Seider, & Dunn, 2008). The treatment regimen for most metabolic diseases on newborn 
screening panels is dietary restriction of protein or addition of a vitamin supplement to 
the diet. If the infant is later discovered to not have the disease, liberalizing the diet easily 
reverses the treatment, and the effects of the restriction are quickly resolved. A 
systematic review of the literature and interviews of pediatricians involved in the 
controversy surrounding PKU treatment demonstrated that benefit of treatment far 
outweighed the burden of risk or cost in the rare overtreated patient (Brosco et al., 2008). 
With KD, however, the treatment is irreversible, carries a high risk of mortality and 
morbidity, and is less effective than initially reported.  
Within the theme of Communication, parents described their experiences 
surrounding initial notification of their infant’s positive KD screen. According to New 
York State Public Health Law, hospitals or birth attendants are required to inform parents 
of the screening test (Test for phenylketonuria and other diseases and conditions. Public 




parent participants were unaware their infant was screened in the nursery. Several studies 
point to the fact that parents are often unaware that newborn screening has occurred 
(Davis, et al., 2006; Grosse, et al., 2010; Bailey and Murray, 2008). For parents in this 
study, this lack of communication about newborn screening made the initial notification 
of a positive KD screen difficult for the parents. 
Furthermore, the lack of information about KD from both the pediatrician and the 
metabolic specialists caused anxiety and lack of trust in the confirmatory results. Every 
parent participant commented about how frightening or confusing the initial notification 
of the positive KD screen was, and suggested that communication of reliable information 
could have made the experience better. Some parents were given information that was 
incorrect, others were not given information because the provider admitted not knowing 
about KD, and others were encouraged to look KD up on the newborn screening website. 
Participants described having more anxiety because they were unable to get information 
from the medical person they trusted, their primary care provider. As newborn screening 
panels are expanded to include more rare diseases, it may be difficult for these providers 
to keep abreast of the changes and take the time to learn about diseases they may never 
encounter. Time constraints in a pediatric practice make explanation of the complex 
genetic information now available from newborn screening difficult (Farrell & Kuruvilla, 
2008; Davis, et al, 2006). 
 Medical stakeholders acknowledged that initial notification of a positive 
screening result could be difficult for parents to hear, and also that this communication 
was not always handled well. These participants agreed that there was insufficient 




argued this was a reason for KD to be removed from the newborn screening panel.  
In the theme of Moral Issues, medical participants voiced concern about treatment 
for KD, a cord blood transplant performed prior to appearance of symptoms. While the 
UCBT study conducted at Duke showed initial promising results, questions about the 
long term effects of this treatment are emerging. There has been growing concern about 
progressive motor deterioration, lack of growth, and developmental delay (Duffner et al., 
2009) and medical participants discussed their ambivalence about recommending this 
treatment to parents. Furthermore, UCBT has only been recommended as treatment for 
the early onset form of KD. For those infants identified with low enzyme activity and 
mutations who have not displayed symptoms, the treatment options remain experimental. 
The concept of KD screening as research was also discussed by the medical 
participants. Many were concerned that KD screening constitutes research, as little is 
known about the natural history of the disease. The addition of KD to New York State’s 
newborn screening panel in 2006 has been described as, “A grand experiment that 
changes lives” (Friedman, 2008). This creates an ethical dilemma for many of the 
medical stakeholders, as research without informed consent is a violation of the principle 
of autonomy. Since newborn screening in New York State is mandated, parental consent 
is not required for a test that ultimately may provide genetic information about carrier 
status or a disease that may not present symptomatically until adulthood. This type of 
predictive genetic testing is discouraged by many professional organizations, particularly 
when a disease has no treatment or cure (Borry, Stultiens, Nys, Cassiman, & Dierickx, 
2006). 




(2008) described dangers of implementing newborn screening tests without adequate 
evaluation of efficacy and safety.  Pilot studies in the context of quality improvement are 
undertaken to determine the efficacy and utility of a new test; however, population-based 
research that includes information about the nature of the disease, risks, benefits, and 
allowing voluntary participation is seldom conducted (Tarini, et al., 2008). As in the case 
of KD, the usual approach to adding a new test to a state newborn screening panel is to 
issue a legislative mandate to preserve public health (2008). Some medical participants 
discussed the fact that because KD is mandated, the need for informed consent no longer 
applies. Indeed, New York State does not require informed consent for newborn 
screening. Grosse, et al. (2010) endorsed a system of consent for those conditions with 
poorly understood natural histories or treatment of uncertain efficacy. These criteria 
certainly apply to KD. Obtaining informed consent for just one disease on the panel, 
however, has been found to be impractical, requiring more than an hour of additional 
staff time to obtain informed consent from parents (Haswega, Ferus, Ojeda, & Au, 2010). 
In California, during a pilot study of expanded screening using tandem mass 
spectrometry in California Researchers found that only 52% of families were offered the 
opportunity to participate in the expanded newborn screening; and, the lack of resources 
(i.e., staff time) to obtain consent was given as the reason for low participation. During 
the 18 months that the pilot study was conducted, it was calculated that 61 infants with a 
disorder detectable by tandem mass spectrometry were likely missed because informed 
consent was not obtained from parents (Feuchtbaum, L., Cunningham, G., Sciortino, S., 
2007).  Therefore, without a large increase in resources to obtain consent, which is not 




not seem practical. 
To assess the stakeholder perceptions of whether KD screening is meeting the 
goals of New York State newborn screening the goal must be broken into three parts. 
Medical participant interviews provided evidence to suggest that the addition of KD to 
the newborn screening panel fulfills the first part of the goal, “early identification of 
children at increased risk for selected metabolic or genetic diseases…”(New York State 
Department of Health, 2006b, p. 1-1). All medical participants agreed that infants at risk 
for KD are being identified.  
 However, questions were raised about KD screening meeting the second part of 
the New York State goal, “so that medical treatment can be promptly initiated to avert 
metabolic crises,” (2003, p. 1-1). While identification of the infants diagnosed with early 
infantile KD provided the option for prompt treatment, medical participants question 
whether crises had been averted, due to the medical procedures involved for UCBT. In 
addition, for the infants identified with low GALC enzyme activity and mutations 
suggesting a later onset of KD, there is no accepted treatment.  
 The third part of the goal, “and prevent irreversible neurological and 
developmental sequelae,” (2003, p. 1-1) was also contested by the medical participants. 
Cord blood transplant, even when initiated promptly, does not appear to prevent 
irreversible neurological and developmental sequelae (Duffner, 2009). Medical 
stakeholders were vocal in their concerns surrounding treatment. All the medical 
participants and program directors acknowledged that UCBT was not ideal. Although the 
treatment could delay onset of symptoms, those who received transplants would 




to that of other disorders on the newborn screening panel to illustrate their concerns. 
Unlike the treatment for those disorders, UCBT is irreversible, has high morbidity and 
carries the risk of death. Medical participants expressed their reluctance recommending 
this treatment option to parents.   
Aim 2. 
Using quantitative methods, sensitivity, specificity and predictive values were 
calculated. Sensitivity is defined as the probability of a positive test given the presence of 
the target disease. Specificity is defined as the proportion of patients who do not have the 
target disease and who screened negative (Strauss, Richardson, Glasziou, & Haynes, 
2005). The positive predictive value represents the precision of the test, in other words, 
the likelihood that a patient with a positive screen actually has KD. The negative 
predictive value represents the accuracy of the test, or whether the initial screening test 
correctly identifies those infants who do not have KD (Greenberg, Daniels, Flanders, 
Eley, & Boring III, 2006). Prevalence was also calculated and describes the number of 
people with a disease in a given population within a specified time frame. In newborn 
screening, it would be ideal to have a test with a sensitivity, specificity, and positive 
predictive value of 100% and a false positive rate of 0 (Sahai & Marsden, 2009). For the 
disorders on newborn screening panels, the cut-off points for reporting are set high in an 
attempt to eliminate false negative results, with the understanding there will be many 
false positive screens. To compensate for the expected number of false positives, the 
confirmatory test for the disorder should have a high positive predictive value to assure 
prompt treatment initiation, and avert morbidity or mortality. Since the positive 




newborn screening panels are rare, the expected positive predictive value may be in the 
single digits (Reinaldo, Zafari, Tortorelli, & Matern, 2006). 
The KD screening program has been effective at identifying infants with low 
enzyme activity with relatively few false positive results. After screening 1,062,000 
infants in four years, the state reported 176 false positive results, and 9 infants with KD 
(enzyme activity ≤0.15 umol/hr/mg protein). Five of those 9 infants have no symptoms of 
KD, but are expected to develop a later onset form based on GALC mutations and 
minimal enzyme activity. Using these values, specificity was calculated at 100%, 
sensitivity was 99%, positive predictive value was 5%, and negative predictive value was 
100%. Prevalence of KD was 1/100,000 births, which is consistent with values reported 
in the literature (Wenger, 2001). However, the state annual reports do not include those 
infants who have enzyme activity between 0.16 and 0.3 umol/hr/mg protein. These 
infants also have either GALC mutations that may develop into late onset KD, or 
mutations of unknown significance. If these infants were included in the state annual 
reports there would be 28 children with disease and 157 false positive results. Using these 
values to calculate the test characteristics, the specificity, sensitivity, and negative 
predictive value did not change, but the positive predictive value rose to 15%. The 
prevalence of KD increased to 3/100,000. Implicit in these calculations is the assumption 
that the infants identified at high or moderate risk will eventually develop KD. Kemper, 
et al. (2010) calculated the positive predictive value using only those infants identified 
with the early infantile form of KD.  However, the legislation mandating KD screening 
does not specify screening for only one form of the disease; therefore all infants 




authentically represent the program. 
 The discrepancy in the annual reports is concerning, because all infants in the 
moderate and high risk categories were referred to neurology to undergo invasive 
neurodiagnostic testing and multiple follow up visits. This sends an ambiguous message 
to several stakeholders. Metabolic specialists inform parents that their child may be at 
risk to develop KD in the future and must be watched closely lest symptoms advance and 
treatment becomes unavailable, but the State doesn’t classify the level of enzyme activity 
as KD. Parents are given a contradictory message that their infant is healthy and 
neurologically normal, but has the potential to develop a progressive neurologic disease. 
They are instructed to be vigilant in watching for symptoms, as well as attending regular 
neurology visits and invasive neurodiagnostic testing. Timmermans and Buchbeinder 
(2010) have described such children with biochemical features of disease but no 
symptoms, as “patients-in-waiting.” If the intent of newborn screening is to identify 
infants early for treatment, then the confirmatory testing must be able to distinguish those 
affected with disease from those who are not affected. If this cannot be done, then there is 
insufficient knowledge about the disease, and further research must be conducted to 
support addition of a disorder to a newborn screening panel.  
 The discrepancy in projected referrals and resulting cost of the KD program was 
apparent in all data sources (see Aim 3 for further discussion of cost). In the text of the 
emergency rule legislation authorizing the addition of KD to the newborn screening 
panel, it was estimated that 25 newborns would be referred annually for confirmatory 
testing of the severe infantile onset form of the disease, and three would be confirmed 




practice, however, these numbers are quite different.  A total of 185 infants were referred 
from August 2006 through July 2010. Of those referred, four infants have been diagnosed 
with early onset KD, another five infants have been categorized as “high risk to develop 
KD,” and the remaining 19 are categorized at “moderate risk to develop KD.” The expert 
consensus recommendation is that infants in both risk groups follow a schedule of 
neurology and neurodiagnostic follow up (Appendix 2). When the emergency rule 
legislation was enacted, the later onset forms of KD were not considered, since the 
literature reported these forms were very rare.  
Aim 3.  
Data sources were selected to represent urban and rural regions of the state, as 
well as a variety of reimbursement sources. The cost categories were chosen to represent 
the procedures and consultations outlined in the consensus protocol developed by the 
Krabbe Consortium (Appendix 2). The annual cost of adding KD to the screening panel 
was estimated to be $750,652. This cost fell below the increased State appropriation of 
$2,000,000 ($11,000,000 in 2006 from $9,000,000 in 2005) (Governor Pataki introduces 
2006-07 executive budget, 2006).  
From the State perspective, the cost of this program may not be excessive, given 
the cost of other disorders on the panel, like severe combined immunodeficiency and 
other inherited T-cell deficiencies (SCID). In March 2011, SCID was added to the New 
York State newborn screening panel. SCID was recommended by the Secretary’s 
Advisory Committee on Heritable Disorders in Newborns and Children and became the 
30th disorder on the uniform screening panel (Bonhomme, 2010). This disorder is similar 




transplant annually (Expansion of the New York State newborn screening panel, 2011), 
he screening laboratory test is similar, and early treatment is most efficacious., A cost 
utility analysis conducted by McGhee, Stiehm, and McCabe (2005), determined the cost 
to detect and treat one case of SCID to be $485,000.   SCID is different than KD in that  
the disorder can be cured with a bone marrow transplant (McGhee, Stiehm, & McCabe, 
2005). 
The average direct medical cost to a family whose infant has a positive 
confirmatory test is estimated at $2,669, which could be excessive, depending on whether 
or not the family has health insurance to cover the costs associated with the positive 
confirmatory testing. This cost could represent hardship for families without insurance or 
with high copays and deductibles. The cost estimate in the emergency rule text for KD 
included confirmatory enzyme testing, spinal fluid analysis (without compensation for 
the lumbar puncture procedure), a single office visit to the specialty center, a genetic 
counseling appointment, and a post-transplant MRI. The total estimate in the emergency 
rule legislation was $550 for an infant with a positive KD screen, and an additional $2700 
for an infant who received a transplant (Expansion of the New York State newborn 
screening panel, 2006). No further follow up was anticipated after a transplant was 
performed.  
To fully appreciate the cost of newborn screening, Hubbard (2007) asserts that the 
following must be considered:  instrumentation; labor and time; initial, repeat, and 
confirmatory testing; screening test sensitivity and specificity; and short and long-term 
follow up. The emergency rule legislation costs were based on the assumption that the 




consider costs subsequent to UCBT, nor the treatment costs. There was also no 
consideration for the total cost of the neurodiagnostic work up for every infant with a 
positive confirmatory test. The asymptomatic infants are referred for ongoing long-term 
follow up including neurodiagnostic tests to monitor for development of KD symptoms.  
Cost analyses evaluating newborn screening tests are used as a decision aid versus 
a rule, and their use is not supported in the US when making policy funding decisions 
(Grosse, Teutsch, and Haddix, 2007).  These authors describe the difficulty in assessing 
economic evaluations for rare disorders included in newborn screening panels, in part 
because often little is known about long-term adverse outcomes of these disorders (2007). 
This is certainly true for the later onset forms of KD.  
Brosco, et al. (2008), discussed a commentary by Joseph Cooper, a political 
scientist attending a conference about PKU screening in 1965, which provides a context 
for considering the costs of newborn screening. Cooper wondered whether the experts 
had lost sight of the larger problems facing the United States and children in particular, 
noting high rates of poverty, limited access to health care, and an unpopular war. He then 
wondered why we have mandatory state laws to identify rare disorders that we do not 
completely understand (Brosco et al., 2008). These comments hold true today, and serve 
as a reminder that we must consider cost in the context of other health issues affecting 
children today.  
Carroll and Downs (2006) calculated the cost of tandem mass spectrometry 
newborn screening for 29 disorders compared screening to be $4839 per QALY saved 
over not screening, and concluded that newborn screening programs as a whole are cost-




recommended by the Secretary’s Advisory Committee on Heritable Conditions in 
Newborns and Children, and KD is not included in that panel.  
Study Implications 
Strengths and Weaknesses 
In qualitative studies, trustworthiness is the measure of scientific rigor, and is 
generally described in terms of credibility, transferability, dependability, and 
confirmability (Miles & Huberman, 1994). Credibility is the concept of congruency of 
research findings and the collected data. Credibility is often compared to the quantitative 
concept of internal validity (Shenton, 2004). One strategy used to achieve credibility was 
the use of the CDC Framework for Program Evaluation in Public Health (1999). This 
framework provided a well-established guidelines and standards of conduct for the 
investigator. To further insure credibility, assurance of study participant anonymity was 
employed to allow for frank and honest discourse. Transferability mirrors the quantitative 
concept of external validity (Shenton, 2004). This was addressed by providing a complete 
description of the documents analyzed, participants, data collection sites, the interview 
process, and time frame of the data collection. Dependability concerns the quality of the 
data collection, analysis and generation of conclusions (Shenton, 2004). To achieve this, 
the research design and methods were reviewed by committee at the investigator’s 
dissertation proposal and by the Columbia University Institutional Review Board prior to 
actual data collection. Confirmability represents how well the study findings are 
supported by the data. This was achieved by a process described by Miles and Huberman 
(1994) as “check-coding.” The dissertation sponsor reviewed these codes in an ongoing 




and the committee. Member checks for medical participants were accomplished by 
presenting findings at the Krabbe Consortium meeting, allowing medical participants the 
opportunity to comment on emerging themes. The investigator contacted a subset of 
parent participants by telephone to review selected portions of the interview transcripts. 
To maximize diversity of the data, the technique of data triangulation was used. 
Data were collected from printed and electronic sources as well as personal interviews. 
Content analysis of supporting documents provided the description of the KD screening 
program as well as providing the background for the interview guides (Appendices 5 and 
6). Face-to-face interviews and telephone interviews were conducted to collect data from 
study participants and analyzed using the qualitative technique of content analysis. 
Quantitative methodology was used to analyze KD screening results and calculate test 
characteristics and cost of the screening program. The triangulation of results provided a 
comprehensive evaluation of the program. 
The use of a single interviewer can be viewed as both a strength and a weakness.  
A single interviewer decreased variability of the interview process. However, the use of a 
single interviewer may introduce bias. The interviewer/investigator is employed as a 
pediatric nurse practitioner at one of the metabolic specialty centers. She is involved with 
reporting KD screening results to parents, interaction with parents during evaluation at 
the specialized care center, and assuring follow-up if confirmatory enzyme testing is 
positive. Every effort was made to assure objectivity and the nature of the investigator’s 
involvement in the newborn screening process was fully disclosed to all participants. A 
thorough description of the data collection process was provided at the dissertation 




and refine the data collection process.  The investigator attended weekly meetings with 
her dissertation advisor to address concerns and to uncover potential confirmation bias of 
the findings. 
Sample bias may be a weakness of this study; subjects were not randomly 
selected, but were selected for their involvement with KD screening. Additionally, none 
of the parent participants in this study had a child in the high-risk category, one child was 
in the moderate risk category, and the remaining children were at no risk to develop KD, 
but could be carriers of KD. Furthermore, those parents and clinicians agreeing to be 
interviewed may have had a particularly bad experience or opinion.  Therefore, the 
perceptions of these participants may not reflect the perceptions of all people involved 
with KD screening. To address potential sample bias, purposive sampling of participants 
was used as a strategy to assure credibility. This strategy allowed for a participant pool 
that had adequately experienced the program under study, and recruitment was conducted 
in both rural and urban areas of New York State to address potential geographic bias. To 
further address the concern that parent participants included only those with favorable or 
unfavorable impressions of the KD screening program, the technique of theoretical 
saturation was used. Theoretical saturation refers to the point at which no new 
information is being found. Furthermore, the participant sample in this study was 
exclusively Caucasian. Due to financial limitations, the investigator was unable to 
provide necessary translation services to recruit families that did not speak English. 
Therefore, only families who spoke English were recruited for participation. This 
requirement eliminated 31 participants from the prospective study sample. Another 




resources, primary pediatricians, although involved in the parental notification of KD 
positive results were not invited to participate.  
There were additional limitations in the cost analysis.  The assumptions made for 
the cost analysis were based on best available data, which may be incomplete. Long-term 
costs and outcomes, including treatment of KD were not included in this analysis, nor 
was the impact of nonmedical costs. For those infants with low GALC activity, the costs 
of medical follow up after confirmatory enzyme testing were also not included in this 
analysis. Although the resulting simple cost analysis is limited, it is the first analysis of 
any cost data associated with KD screening.  
Practice and Policy Recommendations 
 There are a number of important practice and policy recommendations resulting 
from this research. First, public awareness of newborn screening should be improved. 
Despite the legislative mandate that information about newborn screening must be 
provided to parents, there appears to be a lack of awareness about the process. This 
information could be provided to parents during routine obstetrician visits, while parents 
are learning about what to expect when their baby is born. During the hospital stay, both 
nursery personnel and pediatricians could reinforce this information to decrease the 
potential shock of a positive screen. 
Second, communication of positive KD screening results to parents should be 
improved. Because pediatricians may lack both the knowledge and time to properly 
assure parental understanding of a positive KD screen, these results should be 
communicated by the metabolic specialists more familiar with both KD and the complex 




contact with parents, informing them that a metabolic specialist will be contacting them 
with information about their infant’s newborn screen. This could allow the pediatrician to 
facilitate communication while removing the burden of explaining KD to parents and still 
maintaining the role of the medical home. By allowing the metabolic specialist to deliver 
the information about KD, the potential for incorrect information is decreased. 
 Third, since KD testing has the potential to identify infants with low-enzyme 
activity and mutations suggestive of later onset forms of this disease, the moral principle 
of autonomy must be addressed. Instituting an informed consent process for KD testing 
could inform parents of the potential implications of a positive result. Informed consent 
would also address the concerns expressed by the medical participants in this study that 
New York State is conducting research without parental consent. When newborn 
screening and consent have been studied, when consent is offered, very few parents 
decline screening; however,  the process of obtaining consent is resource intense 
(Feuchtbaum, Cunningham, & Sciortino, 2007). For this reason, instituting informed 
consent for routine newborn screening is not recommended.   
Fourth, an improved reporting strategy should be considered. Minimally, a 
category of “indeterminate” should be added to the State Annual Report to represent the 
infants who have developed KD and those who are asymptomatic, but at risk to develop 
disease. This reporting system would more accurately reflect the results of the KD 
screening program. 
 While the addition of KD to New York State’s newborn screening panel has 
identified four infants with the early infantile form of the disease, there have been 24 




confirmatory enzyme test nor the neurodiagnostic tests can accurately provide a 
prognosis or accurate information about onset or severity of symptoms, the ability to 
determine those affected from those unaffected is limited. In addition, the 
neurodiagnostic testing itself carries a level of risk, as the MRI is performed under 
anesthesia. Furthermore, the only available treatment for KD, a UCBT performed prior to 
onset of symptoms, is irreversible and carries a high rate of mortality and morbidity. This 
treatment in now thought to only delay onset of symptoms and it is not known if those 
infants transplanted will eventually die from KD. Therefore, the goal of preventing 
irreversible neurological and developmental sequelae is not being met. Since the goals of 
New York State newborn screening are not satisfied, it is recommended that KD be 
removed from the screening panel. 
Recommendations for Further Study 
There are a number of recommendations for further research resulting from this 
study. First, ongoing concerns regarding UCBT for KD support the need for long term, 
longitudinal follow- up of children who have been transplanted for KD. These studies 
should include quality of life measures, as no studies have been published addressing this 
issue. Furthermore, the infants transplanted in the Duke study (Escolar et al., 2005) all 
had siblings with KD, and parents watched these siblings die. This population is different 
than infants identified through newborn screening, whose families have no experience 
with KD, and this difference may influence the decision to pursue UCBT. As other states 
begin to screen for KD, a national database could be used to track the outcomes of these 
children.  




screening for this disorder, a cost effectiveness analysis should be conducted, comparing 
screening for KD to not screening. This analysis should include direct and indirect costs 
of screening, medical follow up, and current treatment costs for KD, as well as the costs 
for those who have been identified at high or moderate risk, but are asymptomatic.  More 
economic analyses are needed to address the cost of KD testing from the societal 
perspective. While economic evaluations do not affect whether or not a policy is adopted 
in the US, these evaluations can provide scientific, rather than colloquial evidence about 
the costs associated with KD. These cost studies would provide information that is 
currently unavailable for KD and inform those who must make decisions regarding 
allocation of resources. 
To determine the significance of novel mutations and the combinations of 
mutations known to cause later onset disease, studies are needed to follow these infants to 
age of onset. A well-designed longitudinal study should include age of onset of 
symptoms, events surrounding onset of symptoms, and any medical surveillance. These 
studies are vital to gain understanding of the genetic data being discovered as a result of 
KD newborn screening. A national database would be one way to organize these data. 
This type of study may be difficult for several reasons, including: parents not wishing to 
participate in this type of research, families lost to follow up, and insufficient staffing 
resources to collect and enter data. 
Additionally, publication of the mutations discovered as a result of the KD 
newborn screening program in New York should be encouraged. This information could 





A major limitation of this study was the exclusion of non-English speaking 
families. Little is known regarding the effect of newborn screening results and genetic 
information for families from different cultures, and results from studies could help 
providers understand and address concerns that may be currently unrecognized.  
There is a need for well-designed studies that address parental lack of knowledge 
regarding newborn screening. Questions to consider involve; who should inform parents, 
timing of this information, and what information would be most useful. Results from 
these studies could provide information helpful to clinicians and state labs to design 
effective education for parents. Primary care providers may be unaware of the process 
involved with newborn screening and confirmatory testing, and may lack knowledge 
about some disorders included in the panel. The need exists for studies to determine 
educational needs of primary care providers and how best to meet those needs so factual 
information can be provided to parents. Interviews with pediatricians could also be 
conducted to assess their perceptions of KD screening and to determine their knowledge 
of the disease. 
It is unknown what effect a positive KD screen has on parents and families. There 
is evidence to suggest that false positive newborn screen results have psychological 
effects on parents (Waisbren, et al.), but little is known about the effects of “at risk” 
results. For those infants at risk to develop KD, neurologic follow up and neurodiagnostic 
testing continues for years. Research should focus on the impact of KD screening for 
families with infants in the high and moderate risk groups.  
Dissemination Plan 




the evaluation. During the course of this study, preliminary results have been presented in 
an ongoing process. Peer scrutiny of the research was elicited by presentation of 
preliminary study findings at the Lysosomal Storage Diseases Conference in February 
2010 and as a poster presentation at the annual Academy Health meeting in June 2010. 
Preliminary findings were also shared at the Krabbe Consortium meeting in December 
2010. This presentation was used to elicit member checks of the qualitative results from 
the medical participants, allowing the opportunity to comment on the emerging themes. 
 Results of this evaluation will be submitted for publication to reach the broadest 
audience possible. To reach health policy decision makers, a manuscript will be 
submitted to a high impact journal, such as Health Affairs or the American Journal of 
Public Health. To reach an audience of genetic practitioners, a manuscript submission to 
the Journal of Inherited Metabolic Disease is planned. Participants will be notified of any 
publications resulting from this study.  
Conclusions 
 Since 2006, there have been more than 1,000,000 infants screened for KD in New 
York State. While the screening has identified four infants with the early infantile form of 
the disease, there have been 24 others identified with low enzyme activity and mutations 
that may cause later onset forms of the disease, which are poorly understood. This 
unexpected finding suggests that newborns may be diagnosed with a disease that may not 
present symptomatically until adulthood. Unfortunately, the current confirmatory enzyme 
test and neurodiagnostic tests cannot predict onset of disease or severity of symptoms. In 
addition, the only available treatment, a cord blood transplant, is irreversible, has a high 




cost of the program from the perspective of the state is not excessive, cost-effectiveness 
studies are needed to determine the cost of KD screening from the societal perspective, 
and should include treatment and follow up costs.  
 In conclusion, screening for KD does not meet the stated goals of the New York 
State newborn screening program. Parents are in need of more education about newborn 
screening, and pediatricians should work closely with metabolic specialists to deliver 
positive results to parents to minimize the potential for incorrect information. In addition, 
the State should institute a reporting system that adequately reflects all the infants being 
identified as a result of KD screening. More research is needed to understand the 
mutations being identified as a result of KD screening, to follow the long term outcomes 
and quality of life for those children who have received cord blood transplants, and to 
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Appendix 1: Survey Scoring criteria from the ACMG Task Force on Newborn Screening 
(Brameld, K. 2006) 
 
The Condition/Disorder Categories Score 








Signs & symptoms clinically 
identifiable in the first 48 hours 
Never 100 
<25% of the cases 75 
<50% of the cases 50 
<75% of the cases 25 
Always 0 







The Test for the Condition/Disorder 
Does a sensitive & specific 







Detectable in neonatal blood spots or by a simple 
nursery physical method 
100 
High throughput >200/day/FTE 50 
Overall analytical cost <$1 per test/condition 50 
Multiple analyses relevant to one condition in same 
spot  
50 




Multiple conditions detected by the same analytes 50 
Multiple conditions detected by the same test 
(multiplex pattern) 
200 
The Condition/Disorder Treatment 




Treatment exists, but availability is limited 25 
 
No treatment is available or necessary 0 







Potential efficacy of existing 
treatment 
 
To prevent ALL negative consequences 200 
 
To prevent MOST negative consequences 100 
To prevent SOME negative consequences 50 
Treatment efficacy is not known 0 
Benefits of early intervention 
(Individual outcome) 
Clear evidence that early intervention resulting from 




Some evidence that early intervention resulting from 




No evidence that early intervention resulting from 
newborn screening optimizes outcome 
0 
Benefits of early intervention 
(Family & society) 
Early intervention provides clear benefits to family & 
society (education, understanding prevalence, 











No benefits to family and society 0 
The Screening Program 


































Acute  management of  available in city in a few 
centers 
0 
Simplicity of therapy Management at primary care or family level 200 
 
Requires periodic involvement of a specialist 100 
 



























Appendix 2: Krabbe Consortium Evaluation Schedule and Point System for UCBT 
 
Evaluation Schedule  (for infants with positive confirmatory enzyme results) 
 
Neurological Evaluation                  Neurodiagnostic* 
 
     Year 1    Q Month            Baseline, then Q4 months X 3 
High Risk  
(0.0-0.15)    Year 2    Q 3 Months            PRN**  




Moderate Risk    Year 1   Q 3 Months               Baseline, then PRN** 
(0.16-0.29)            





*MRI, Lumbar Puncture, Nerve Conduction Velocity, Brainstem Auditory Evoked 
Responses 
 





 MRI Brain 
o 4 or 5 mm slices with 1 mm interslice gap or no gap 
o Axial unenhanced T1 weighted images 
o Axial flair images 
o Sagittal proton-density and T2 weighted images 
 
 Lumbar Puncture 




o Abnormal if (1) prolongation interpeak latency I-V or (2) loss waves III-V 
 
 Nerve Conduction Velocity (one sensory and one motor in one upper and one 
lower extremity) 
o Abnormal if: 
 Absent response 




 Prolonged distal latency 
 Slow conduction velocity 
 Conduction block > 50% reduction of CMAP amplitude proximal 
vs. distal (partial) 




Point System For UCBT Referral  
 
Consider Transplantation for scores > 4 Points                          
          Points 
• Abnormal Neurologic Exam            2 
• Positive MRI                2 
• Positive LP (Increased Protein)             2 
• Positive NCV                1 
• Positive BAER               1 





























Appendix 3: Parent Abstract and Invitation Letter 
 
 
Information About the Krabbe Disease Screening Program Evaluation Study: 
 
The purpose of this study is to conduct a formal program evaluation of newborn 
screening for Krabbe disease in New York State using the CDC Framework for Program 
Evaluation in Public Health. The aims of this study will be: 1) Assess if Krabbe disease 
screening is meeting the stated goals of the New York State newborn screening program 
for each of the stakeholders using this program 2) Assess the Krabbe disease test 
characteristics with the most recent data available, and 3) Assess the cost to identify one 
true positive Krabbe disease screening result. 
 
Members of various stakeholder groups will be invited to participate in one to two 
hour audio-taped interviews. Stakeholders include individuals with a child who screened 
positive for Krabbe disease, nurse practitioners, genetic counselors, medical directors, 
parent advocacy group representatives, and directors of operations involved in the Krabbe 
disease screening program. These stakeholders represent people involved in program 
operations, people served or affected by the program, or people in a position to make 
decisions about the program. Gathering information directly from stakeholders is thought 
to provide relevant data for analyzing the effectiveness of the Krabbe disease screening 
program as described by New York State. 
 
The student investigator will conduct opened ended interviews using guides designed 
for each stakeholder group. The interviews will be transcribed and analyzed using the 
qualitative method of content analysis. It is expected that 28 interviews of about 1 hour 
per interview will be conducted, with members from each stakeholder group represented. 
 
Bobbie Salveson is the student investigator for this study. She is a pediatric nurse 
practitioner pursuing a research doctorate at Columbia University School of Nursing, 
with an interest in health policy. She is involved in the newborn screening program as the 




York City.  If you are interested in participating in this study, please send the stamped 
postcard and she will contact you to arrange an interview at a time and place convenient 





In August of 2006, New York State became the first and only state to implement testing 
for Krabbe disease, a rare neurological disorder. This program has screened over 800,000 
infants since that time, and other states are considering adding this test to their newborn 
screening panel. The need exists for an objective evaluation of this program to provide 
information to people involved in health policy decision-making. Therefore, a research 
study is being conducted to provide this information. 
 
The purpose of this study is to conduct a formal program evaluation of newborn 
screening for Krabbe disease in New York State using the CDC Framework for Program 
Evaluation in Public Health. Stakeholders in the Krabbe disease-screening program will 
be contacted and interviewed using semi-structured interview guides. These interviews 
will be analyzed using qualitative research methods, reviewed, and the results of the 
study will be published in an academic journal. It is hoped that this research study will 
provide information for public health decision makers considering the addition of 
screening for Krabbe disease in newborns. 
 
You have been invited to participate in this study because you are a stakeholder in the 
Krabbe disease-screening program, and your child was evaluated at the Metabolic 
Specialty Center. Stakeholders include individuals with a child who screened positive for 
Krabbe disease, nurse practitioners, genetic counselors, medical directors, parent 
advocacy group representatives, and directors of operations involved in the Krabbe 
disease-screening program.   
 
If you are interested in participating, please return the stamped postcard enclosed, and the 
investigator will contact you to arrange an interview at a place and time convenient to 
you. I will have no way of knowing whether you responded, or participated in the study, 
and will not contact you again regarding your participation. The investigator of the study 
will contact you confidentially, and you are under no obligation to participate.  
 



















































Appendix 5: Initial Interview Guides 
 
Stakeholder Group: Those involved in program operations (Medical) 
Consent Signed: ___________________________________________ 
Date & Time of Interview: ___________________________________ 
Interview Location: ___________________________________ 
Demographic information:  Years in practice___________ 
    Position__________________ 
 
 Political Process
 What was your role in implementing the Krabbe disease screening program?
 
        Information Seeking 
 Tell me about your experience with the program since screening began.
 
       Projected Referrals 
 Tell me about any newborns referred that screened positive? 
 
  How many? 
  What did the confirmatory testing show? 
 
 Parent Notification 
 Describe your contact with parents who have had children that screened positive
 
 Use of Consortium Protocol - Consistency
 Tell me about your Krabbe Disease protocol?
 
  How is the protocol used in your setting? 
  
        Krabbe Consortium Feedback 
 Are there any improvements you would like to see with the program?
 
  Describe any changes made to the program since implementation 
 
     Meeting goals of NYS newborn screening 















Stakeholder Group: Those served or affected by the program (Parent) 
 
Consent Signed: ___________________________________________ 
Date & Time of Interview: ___________________________________ 
 Interview Location: ___________________________________ 
Demographic Information: Gender___________ Age__________ Number of 
children_______ Metabolic Referral Center______________ 
 
Parent Notification  
How did you first hear that your child had a positive newborn screen?
 Were you aware your child had been screened in the nursery? 
 
       Information Seeking 
Describe your experience with the follow-up for Krabbe disease screening
 
Indirect Costs  
Can you tell me about any difficulties or inconveniences you experienced associated 
with the follow-up?
   Direct Costs 
 Tell me about any medical costs associated with the follow up: 
       
      Clarity of Information 
What kind of results and recommendations did you receive from the providers caring 
for your child?
 
Impact of Screening 
Since the screening, can you tell me about anything that has changed in your child’s 
health?
 
 And with your family? 
 
Political Process 

















Appendix 6: Final Interview Guides 
 
Stakeholder Group:  Those served or affected by the program (med) 
Consent Signed: ___________________________________________ 
Date & Time of Interview: ___________________________________ 
 Interview Location: ___________________________________ 
Demographic Information: Years in Practice: ____________________________ 
Position: _________________________________ 
Political Process 
Tell me about your role in implementing the Krabbe disease screening program 
 
Information Seeking 
What has been your experience with the program since screening began? 
 
Projected Referrals 
Tell me about any newborns referred to you for positive screens 
And their confirmatory testing?  
 
Lessons Learned 
Do you have any concerns about these results? 
 
Parent Notification 
Describe your contact with parents of children who have screened positive. 
From initial notification to discharge – added to clarify and assess process 
 
Use of Consortium Protocol - Consistency
Describe your center’s use of the follow up protocol established by the Krabbe disease 
Consortium: 
To the best of your knowledge – how are families adhering to the 
recommendations? discharge – added to clarify and assess process 
 
Parent Notification 
Describe any issues parents have had with the screening process 
 
Krabbe Consortium Feedback 
Any changes you’ve seen based on feedback from the Consortium meetings? 
 
Political Process 
Are there any improvements you would like to see with this program? 
 
Meeting goals of NYS newborn screening 
How do you think Krabbe disease screening fits the newborn screening model established 







Meeting goals of NYS newborn screening 
How does Krabbe disease screening compare to screening for other disorders? 
 
Meeting goals of NYS newborn screening 
Since implementation – can you think of anything that has been learned that could be 
applied to make the screening process as intended? 
 
Lessons Learned 
What kind of issues in this program have been frustrating for you as a physician? 
 
Lessons Learned 
Describe the successes of the Krabbe screening program 
 
Political Process 
If you were offering guidance to decision-makers in other states, what would you tell 



































Stakeholder Group:  Those served or affected by the program (parent) 
 
Consent Signed: ___________________________________________ 
Date & Time of Interview: ___________________________________ 
Interview Location: ___________________________________ 
 
Demographic Information: Gender___________ Age__________ Number of 
























Impact of Screening 
Tell	me	about	any	concerns	you	may	have	–	are	these	related	to	the	Krabbe	
screening	process? 
 
Political Process 
Do	you	have	any	suggestions	for	other	parents	going	through	this	process? 
 
 
 
 
 
 
 
